WO2005019240A2 - Melanin concentrating hormone receptor antagonists - Google Patents

Melanin concentrating hormone receptor antagonists Download PDF

Info

Publication number
WO2005019240A2
WO2005019240A2 PCT/US2004/025970 US2004025970W WO2005019240A2 WO 2005019240 A2 WO2005019240 A2 WO 2005019240A2 US 2004025970 W US2004025970 W US 2004025970W WO 2005019240 A2 WO2005019240 A2 WO 2005019240A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
hydrogen
alkyl
nitrogen
ethyl
Prior art date
Application number
PCT/US2004/025970
Other languages
French (fr)
Other versions
WO2005019240A3 (en
Inventor
Paul Tempest
Christopher Hulme
Vu Ma
Original Assignee
Amgen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen, Inc. filed Critical Amgen, Inc.
Priority to EP04780754A priority Critical patent/EP1654225A4/en
Priority to CA002534428A priority patent/CA2534428A1/en
Priority to JP2006523322A priority patent/JP2007502283A/en
Priority to MXPA06001638A priority patent/MXPA06001638A/en
Priority to AU2004266228A priority patent/AU2004266228A1/en
Publication of WO2005019240A2 publication Critical patent/WO2005019240A2/en
Publication of WO2005019240A3 publication Critical patent/WO2005019240A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Definitions

  • BMI body mass index
  • a gain of approximately 10 to 20 pounds results in an increased risk of coronary heart disease (nonfatal myocardial infarction and death) of 1.25 times in women and 1.6 times in men.
  • Higher levels of body weight gain of 22 pounds in men and 44 pounds in women result in an increased coronary heart disease risk of 1.75 and 2.65, respectively.
  • the risk of developing endometrial cancer is increased by more than six times.
  • Overweight and obesity are also known to exacerbate many chronic conditions such as hypertension and elevated cholesterol. Overweight and obese individuals also may suffer from social stigmatization, discrimination, and poor body image. Although obesity-associated morbidities occur most frequently in adults, important consequences of excess weight as well as antecedents of adult disease occur in overweight children and adolescents.
  • MCH Melanin-concentrating hormone
  • MCH energy homeostasis
  • MCH 1 receptor and MCH 2 receptor Two receptors have been identified in MCH, and are designated MCH 1 receptor and MCH 2 receptor.
  • MCH 1 and MCH 2 receptors are G protein-coupled receptors (GPCRs) believed to be responsible for the actions of MCH.
  • G proteins are heterotrimeric proteins that control cellular responses to stimuli by cycling between a GTP-bound active state, which regulates the activity of a number of effector proteins, and a GDP-bound inactive state. GPCRs accelerate activation of the G protein by increasing the GDP/GTP exchange rate.
  • MCH 1 receptor-deficient mice have normal body weights, yet are lean and have reduced fat mass. Surprisingly, MCH 1 receptor-deficient mice are hyperphagic when maintained on regular chow, and their leanness is a consequence of hyperactivity and altered metabolism. Consistent with the hyperactivity, MCH 1 receptor-deficient mice are less susceptible to diet-induced obesity. Importantly, chronic central infusions of MCH induce hyperphagia and mild obesity in wild-type mice, but not in MCH 1 receptor-deficient mice. Marsh et al., Proc. Nat. Acad. Sci., 99(5), 3241 (2002).
  • MCH has been shown to be an important regulator of food intake and energy balance
  • compounds capable of modulating the activity of MCH receptors are highly desirable for the treatment of eating disorders and metabolic disorders .
  • PCT Publication No. WO 02/04433 describes phenylcycloalkylmethylamino and phenylalkenylamino derivatives as modulators of MCH 1 receptors useful in the treatment of certain metabolic, feeding and sexual disorders.
  • U.S. Patent No. 6,472,394 describes the use of amide derivatives of 1, 4-disubstituted piperidine as MCH antagonists for the treatment of obesity and diabetes.
  • the provision of melanin concentrating hormone receptor antagonists may be noted the provision of melanin concentrating hormone receptor antagonists; the provision of pharmaceutical compositions comprising melanin concentrating hormone receptor antagonists; the provision of methods of treating, preventing, or otherwise ameliorating melanin concentrating hormone-mediated disorders in a subject; the provision of methods for treating, preventing or otherwise ameliorating obesity in a subject; and the provision of methods of achieving sustained body weight loss in a subject.
  • the present invention is directed to a melanin concentrating hormone receptor antagonist of Formula I as defined herein.
  • the present invention is also directed to pharmaceutical compositions comprising a compound of Formula I, as defined herein, and a pharmaceutically acceptable carrier, adjuvant, or diluent.
  • the present invention is also directed to a method of inhibiting a GPCR, comprising contacting a compound of Formula I, as defined herein, with a GPCR, wherein the compound of Formula I is present at a concentration sufficient to inhibit the binding of a GPCR ligand in vi tro .
  • This method includes inhibiting a GPCR in vivo, e.g., in a subject given an amount of a compound of Formula I that would be sufficient to inhibit the binding of a ligand to the GCPR in vi tro .
  • GPCR families Acetylcholine muscarinic, Adenosine, adrenergic, adrenergic, alpha-adrenergic, angiotensin, AR, Cannabinoid, DA, dopamine, His, imidazoline, Leukotriene, mAch, MCH, Opioid, serotonergic, serotonin, and Somatostatin.
  • Inhibition of the binding of a GPCR ligand to GPCRs is useful in the treatment of numerous disorders, including digestive tract disorders; mucolytic asthma; arrhythmia; ischemia; reperfusion injury; bronchospasm associated with asthma, emphysema and chronic bronchitis; acute and chronic respiratory diseases, including cystic fibrosis; cardiostimulant ; chronic bronchitis; neurological depression; heart failure; benign prostate hypertrophy; diabetes; muscle spasm; myocardial infarction; stroke; Alzheimer's disease; anorexia; cachexia; multiple sclerosis; hyperprolactinemia; psychotropism; mydriasis in ocular examination and surgery; deficitary and productive schizophrenia, psychasthenia and non- endogenous depression; kidney disease; vasodilation; chronic gastritis; glaucoma; depression; rhinitis, including allergic rhinitis; pain, including cancer pain, musculoskeletal pain, post-
  • the present invention is also directed to methods of inhibiting the binding of MCH to MCH receptors comprising contacting a compound of Formula I with cells expressing MCH receptors, wherein the compound is present at a concentration sufficient to inhibit MCH binding to MCH receptors in vitro.
  • This method includes inhibiting the binding of MCH to MCH receptors in vivo, e.g., in a subject given an amount of a compound of Formula I that would be sufficient to inhibit the binding of MCH to the MCH receptors in vi tro.
  • the amount of a compound of Formula I that would be sufficient to inhibit the binding of MCH to the MCH receptor in vi tro may be readily determined via a MCH receptor binding assay, such as the assay described hereinbelow in Example 24.
  • the present invention is also directed to methods for altering the signal-transducing activity of MCH receptors, particularly the MCH receptor-mediated release of intracellular calcium, said method comprising exposing cells expressing such receptors to an effective amount of a compound of the invention.
  • This method includes altering the signal-transducing activity of MCH receptors in vivo, e.g., in a subject given an amount of a compound of Formula I that would be sufficient to alter the signal-transducing activity of MCH receptors in vi tro .
  • the amount of a compound that would be sufficient to alter the signal-transducing activity of MCH receptors may be determined via a MCH receptor signal transduction assay, such as the calcium mobilization assay described hereinbelow in Example 23.
  • the present invention is also directed to methods of using compounds of Formula I and appropriately labeled derivatives thereof as standards and reagents in determining the ability of a potential pharmaceutical to bind to MCH receptor.
  • the present invention is also directed to methods of treating, preventing, or otherwise ameliorating melanin concentrating hormone-mediated disorders in a subject, the method comprising administering a compound of Formula I or a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically-acceptable carrier, adjuvant, or diluent to said subject.
  • the present invention is also directed to methods of treating or preventing obesity in a subject, the method comprising administering a compound of Formula I or a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically-acceptable carrier, adjuvant, or diluent to said subject.
  • the present invention is also directed to methods of treating or preventing conditions such as feeding disorders, including obesity, bulimia and bulimia nervosa; sexual or reproductive disorders; depression and anxiety; epileptic seizure; hypertension; cerebral hemorrhage; congestive heart failure; sleep disturbances; or any condition in which antagonism of an MCH receptor is beneficial .
  • the present invention is also directed to methods of treating eating disorders, particularly obesity and bulimia nervosa, comprising administering to a subject in need of such treatment a compound of Formula I in combination with leptin, a leptin receptor agonist, or a melanocortin receptor 4 (MC4) agonist .
  • the present invention is also directed to methods of using compounds of Formula I as positive controls in assays for activity of GPCRs, particularly MCH.
  • the present invention is also directed to methods of using appropriately labeled compounds of Formula I as probes for the localization of GPCRs, particularly MCH, in tissue sections.
  • alkyl where used alone or within other terms such as “haloalkyl”, “alkylsulfonyl” , “alkoxyalkyl” and “hydroxyalkyl”, is a linear or branched radical having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are “lower alkyl” radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about six carbon atoms.
  • radicals examples include methyl, ethyl, propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, sec- butyl, and tert-butyl) , pentyl (e.g., n-pentyl and iso-amyl) , hexyl, and the like.
  • cycloalkyl is a saturated carbocyclic radical having three to twelve carbon atoms.
  • the cycloalkyl radical may be mono-, bi-, or tricyclic.
  • More preferred cycloalkyl radicals are "lower cycloalkyl” radicals having three to about eight carbon atoms. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • alkenyl is a linear or branched radical having at least one carbon-carbon double bond and having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkyl radicals are "lower alkenyl” radicals having two to about six carbon atoms. Examples of alkenyl radicals include ethenyl, propenyl, allyl, butenyl and 4-methylbutenyl .
  • alkenyl and “lower alkenyl” also are radicals having "cis” and “trans” orientations, or alternatively, “E” and “Z” orientations.
  • cycloalkenyl is a partially unsaturated carbocyclic radical having three to twelve carbon atoms.
  • the cycloalkenyl radicals may be mono-, bi-, or tricyclic. More preferred cycloalkenyl radicals are “lower cycloalkenyl” radicals having four to about eight carbon atoms. Examples of such radicals include cyclobutenyl, cyclopentenyl, cyclopentadienyl, and cyclohexenyl .
  • alkynyl is a linear or branched radical having at least one carbon-carbon triple bond and having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkynyl radicals are "lower alkynyl” radicals having two to about ten carbon atoms. Most preferred are lower alkynyl radicals having two to about six carbon atoms. Examples of such radicals include propargyl, butynyl, and the like. [0031] The terms "carboxy” or “carboxyl”, whether used alone or with other terms, such as “carboxyalkyl” , is -C0 2 H.
  • carboxyalkyl is an alkyl radical as defined above substituted with a carboxy radical. More preferred are “lower carboxyalkyl” radicals, which are lower alkyl radicals as defined above substituted with a carboxy radical, and may be additionally substituted on the alkyl radical with halo. Examples of such lower carboxyalkyl radicals include carboxymethyl , carboxyethyl and carboxypropyl .
  • halo is a halogen such as fluorine, chlorine, bromine or iodine.
  • haloalkyl is an alkyl radical as defined above wherein any one or more of the carbon atoms is substituted with halo as defined above. Specifically included are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals.
  • a monohaloalkyl radical for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical.
  • Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. More preferred haloalkyl radicals are "lower haloalkyl" having one to six carbon atoms.
  • lower haloalkyl radicals include fluoromethyl , difluoromethyl, trifluoromethyl, chlor ⁇ methyl, dichloromethyl, trichloromethyl , trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl , difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl .
  • alkoxy and “alkyloxy” are linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms.
  • More preferred alkoxy radicals are "lower alkoxy" radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy.
  • the "alkoxy" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy radicals.
  • More preferred haloalkoxy radicals are "lower haloalkoxy" radicals having one to six carbon atoms and one or more halo radicals. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and fluoropropoxy.
  • alkoxyalkyl is an alkyl radical having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and polyalkoxyalkyl radicals. More preferred alkoxyalkyl radicals are "lower alkoxyalkyl” radicals having two to twelve carbon atoms.
  • radicals examples include methoxymethyl , methoxyethyl , methoxypropyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , dimethoxymethyl , dimethoxyethyl , methoxy (ethoxy) ethyl, dimethoxypropyl , and methoxy (ethoxy) propyl .
  • alkoxycarbonyl is a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a carbonyl radical, i.e., an ester radical. More preferred are "lower alkoxycarbonyl" radicals with alkyl portions having one to six carbons.
  • lower alkoxycarbonyl radicals include substituted or unsubstituted methoxycarbonyl , ethoxycarbonyl , propoxycarbonyl , butoxycarbonyl and hexyloxycarbonyl .
  • hydroxyalkyl is a linear or branched alkyl radical having one to about ten carbon atoms, any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are "lower hydroxyalkyl" radicals having one to six carbon atoms and one or more hydroxyl radicals.
  • alkylamino is an amino group that has been substituted with one or two alkyl radicals.
  • Preferred are "lower N-alkylamino" radicals having alkyl portions having one to six carbon atoms. Suitable lower alkylamino may be mono- or dialkylamino, such as N-methylamino, N-ethylamino, N,N- dimethylamino, N,N-diethylamino or the like.
  • alkylaminoalkyl is a radical having one or more alkyl radicals attached to the nitrogen atom of an aminoalkyl radical .
  • alkylaminocarbonyl is an aminocarbonyl group that has been substituted with one or two alkyl radicals on the amino nitrogen atom.
  • N-alkylaminocarbonyl N,N-dialkylaminocarbonyl radicals.
  • More preferred are “lower N-alkylaminocarbonyl” and “lower N,N-dialkylaminocarbonyl” radicals with lower alkyl portions as defined above.
  • alkylthio is a radical containing an alkyl radical of one to about ten carbon atoms attached to a divalent sulfur atom. More preferred alkylthio radicals are "lower alkylthio" radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthio radicals are methylthio, ethylthio, propylthio, butylthio and hexylthio. [0043] The term "alkylthioalkyl” is a radical containing an alkylthio radical attached through the divalent sulfur atom to an alkyl radical of one to about ten carbon atoms .
  • alkylthioalkyl radicals are "lower alkylthioalkyl” radicals having alkyl radicals of one to six carbon atoms.
  • lower alkylthioalkyl radicals include methylthiomethyl, methylthioethyl, ethylthioethyl, and ethylthiopropyl .
  • alkylsulfinyl radicals are "lower alkylsulfinyl” radicals having alkyl radicals of one to six carbon atoms.
  • lower alkylsulfinyl radicals include methylsulfinyl, ethylsulfinyl, butylsulfinyl and hexylsulfinyl .
  • aminoalkyl is an alkyl radical substituted with one or more amino radicals. More preferred are "lower aminoalkyl” radicals of one to six carbon atoms. Examples of such radicals include aminomethyl, aminoethyl, and the like.
  • aryl alone or in combination, is a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused, and wherein at least one of the rings is aromatic.
  • aryl includes aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl.
  • Aryl moieties may also be substituted at a substitutable position with one or more substituents selected independently from alkyl, alkoxyalkyl, alkylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, a inocarbonylalkyl , alkoxy, aralkoxy, hydroxyl, amino, halo, nitro, alkylamino, acyl, cyano, carboxy, aminocarbonyl, alkoxycarbonyl and aralkoxycarbonyl .
  • heterocyclyl and “heterocyclo” are saturated or partially unsaturated heteroatom-containing ring- shaped radicals having one, two, or three rings wherein such rings may be attached together in a pendent manner or may be fused, where the heteroatoms may be selected from nitrogen, sulfur and oxygen.
  • saturated heterocyclyl and heterocyclo radicals include saturated 3- to 6-membered heteromonocylic radicals containing one to four nitrogen atoms (e.g., pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.); saturated 3- to 6-membered heteromonocyclic group containing one to two oxygen atoms and one to three nitrogen atoms (e.g., morpholinyl, etc.); saturated 3- to 6-membered heteromonocyclic group containing one to two sulfur atoms and one to three nitrogen atoms (e.g., thiazolidinyl, etc.).
  • saturated 3- to 6-membered heteromonocylic radicals containing one to four nitrogen atoms e.g., pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.
  • heteroaryl is an aromatic heteroatom- containing ring-shaped radical having one, two, or three rings wherein at least one ring is aromatic.
  • heteroaryl radicals include unsaturated 3- to 6- membered heteromonocyclic group containing one to four nitrogen atoms, e.g., pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1, 2 , 4-triazolyl, 1H- 1,2, 3 -triazolyl, 2H-1, 2 , 3 -triazolyl , etc.) tetrazolyl (e.g.
  • heteroaryl also includes radicals where heteroaryl radicals are fused with aryl radicals.
  • fused bicyclic radicals include benzofuran, benzothiophene, and the like.
  • Said heterocyclyl group may be substituted at a substitutable position with one or more substituents selected independently from alkyl, hydroxyl, halo, alkoxy, oxo, amino and alkylamino.
  • heterocyclylalkyl and “heterocycloalkyl” are saturated and partially unsaturated heterocyclyl-substituted alkyl radicals, such as pyrrolidinylmethyl, and heteroaryl- substituted alkyl radicals, such as pyridylmethyl , quinolylmethyl , thienylmethyl , furylethyl, and quinolylethyl .
  • the heteroaryl in said heteroaralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy.
  • acyl is a radical provided by the residue after removal of hydroxyl from an organic acid.
  • alkanoyl and aroyl radicals examples include alkanoyl and aroyl radicals.
  • alkanoyl or “alkylcarbonyl” are alkyl radicals as defined herein attached to a carbonyl radical. Examples of such alkanoyl radicals include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl , and trifluoroacetyl .
  • arylcarbonyl also called “aroyl”
  • aralkylcarbonyl include radicals having aryl or aralkyl radicals, as defined herein, attached to a carbonyl radical. Examples of such radicals include substituted or unsubstituted phenylcarbonyl, naththoyl, and benzylcarbonyl . The aryl in said aroyl and aralkylcarbonyl radicals may be additionally substituted.
  • aralkoxy is an aralkyl radical as defined herein attached through an oxygen atom to other radicals.
  • aralkoxyalkyl is an aralkoxy radical as defined herein attached through an oxygen atom to an alkyl radical .
  • aralkyl and arylalkyl are aryl- substituted alkyl radicals such as benzyl, diphenylmethyl , triphenylmethyl , phenylethyl, and diphenylethyl .
  • the aryl in said aralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy.
  • benzyl and phenylmethyl are interchangeable .
  • aralkylamino is an aralkyl radical as defined herein attached through an amino nitrogen atom to other radicals.
  • N-arylaminoalkyl and “N-aryl-N-alkyl- aminoalkyl” are amino groups which have been substituted with one aryl radical or one aryl and one alkyl radical, respectively, and having the amino group attached to an alkyl radical. Examples of such radicals include N-phenylaminomethyl and N-phenyl-N-methylaminomethyl .
  • aralkylthio is an aralkyl radical attached to a sulfur atom.
  • aralkylthioalkyl is an aralkylthio radical attached through a sulfur atom to an alkyl radical.
  • arylamino is an amino group that has been substituted with one or two aryl radicals. An example of such arylamino radicals is N-phenylamino .
  • the "arylamino” radicals may be further substituted on the aryl ring portion of the radical .
  • aryloxyalkyl is a radical having an aryl radical attached to an alkyl radical through a divalent oxygen atom.
  • arylthioalkyl is a radical having an aryl radical attached to an alkyl radical through a divalent sulfur atom.
  • sulfonyl is a divalent -S0 2 - radical.
  • alkylsulfonyl is an alkyl radical attached to a sulfonyl radical, where alkyl is defined as above. More preferred alkylsulfonyl radicals are "lower alkylsulfonyl" radicals having one to six carbon atoms.
  • alkylsulfonyl radicals examples include methylsulfonyl, ethylsulfonyl and propylsulfonyl .
  • the "alkylsulfonyl” radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkylsulfonyl radicals.
  • halo atoms such as fluoro, chloro or bromo
  • pharmaceutically acceptable is used adjectivally herein to mean that the modified noun is appropriate for use in a pharmaceutical product; that is the "pharmaceutically-acceptable” material is relatively safe and/or non-toxic, though not necessarily providing a separable therapeutic benefit by itself.
  • Pharmaceutically-acceptable cations include metallic ions and organic ions. More preferred metallic ions include, but are not limited to, appropriate alkali metal salts, alkaline earth metal salts and other physiologically-acceptable metal ions. Exemplary ions include aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, in their usual valences.
  • Preferred organic ions include protonated tertiary amines and quaternary ammonium cations, including in part, trimethylamine, diethylamine, N,N'- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.
  • Exemplary pharmaceutically acceptable acids include without limitation hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulfonic acid, acetic acid, formic acid, tartaric acid, maleic acid, malic acid, citric acid, isocitric acid, succinic acid, lactic acid, gluconic acid, glucuronic acid, pyruvic acid, oxalacetic acid, fumaric acid, propionic acid, aspartic acid, glutamic acid, benzoic acid, and the like.
  • prodrug refers to a chemical compound that can be converted into a therapeutic compound by metabolic or simple chemical processes within the body of the subject.
  • the term "subject" for purposes of treatment or prevention includes any human or animal subject who is in need of treatment.
  • the subject can be a domestic livestock species, a laboratory animal species, a zoo animal or a companion animal. In one embodiment, the subject is a mammal. In another embodiment, the mammal is a human being.
  • PBS phosphate buffered saline.
  • HEPES phosphate buffered saline
  • HEPBS stands for N-2- hydroxyethylpiperazine-N' -2-ethanesulfonic acid.
  • BSA bovine serum albumin.
  • STI soybean trypsin inhibitor.
  • Pefabloc stands for (4- (2- aminoethyl) benzenesulfonylfluoride, HCl salt.
  • Phosphoramidon stands for N- ⁇ -L- rhamnopyranosyloxy (hydroxyphosphinyl) -L-leucyl-L-tryptophan.
  • FCC stands for flash column chromatography.
  • Ki stands for inhibitory rate constant.
  • FLIPR stands for fluorometric imaging plate reader.
  • HEK 293 stands for the human embryonic kidney 293 cell line.
  • the term "HOBt” stands for 1-Hydroxybenzotriazole hydrate .
  • the term “MeOH” stands for methanol.
  • the term “TFA” stands for trifluoroacetic acid.
  • the MCH receptor antagonists employed in the present invention can exist in tautomeric, geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-geometric isomers, E- and Z-geometric isomers, R- and S-enantiomers, diastereomers, d- and 1-isomers, the racemic mixtures thereof and other mixtures thereof .
  • cis and trans denote a form of geometric isomerism in which two carbon atoms connected by a double bond and each substituted by a hydrogen and another group, will each have a hydrogen atom on the same side of the double bond ("cis") or on opposite sides of the double bond ("trans") .
  • Some of the compounds described herein contain alkenyl groups, and are meant to include both cis and trans or “E” and “Z” geometric forms.
  • some of the compounds described herein contain one or more stereocenters and are meant to include R, S, and mixtures or R and S forms for each stereocenter present .
  • the MCH receptor antagonists utilized in the present invention may be in the form of free bases or pharmaceutically- acceptable acid addition salts thereof.
  • pharmaceutically-acceptable salts are salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt may vary, provided that it is pharmaceutically acceptable.
  • Suitable pharmaceutically- acceptable acid addition salts of compounds for use in the present methods may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid.
  • organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic) , methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, algenic, " hydroxybutyric, salicylic, galactaric and galactu
  • Suitable pharmaceutically-acceptable base addition salts of compounds of use in the present methods include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) , and procaine. All of these salts may be prepared by conventional means from the corresponding compound by reacting, for example, the appropriate acid or base with the compound of any Formula set forth herein.
  • the MCH receptor antagonists useful in the practice of the present invention can be formulated into pharmaceutical compositions and administered by any means that will deliver a therapeutically effective dose.
  • compositions can be administered orally, parenterally, by inhalation spray, rectally, intradermally, transdermally, or topically, in dosage unit formulations containing conventional nontoxic pharmaceutically-acceptable carriers, adjuvants, and vehicles as desired.
  • Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques. Formulation of drugs is discussed in, e.g., Hoover, Remington's Pharmaceutical Sciences, (1975), and Liberman & Lach an, Eds., Pharmaceutical Dosage Forms, (1980) .
  • Injectable preparations for example, sterile injectable aqueous or oleaginous suspensions, can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally-acceptable diluent or solvent.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed, including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are useful in the preparation of injectables.
  • Suppositories for rectal administration of the compounds discussed herein can be prepared by mixing the active agent with a suitable non-irritating excipient such as cocoa butter, synthetic mono-, di-, or triglycerides, fatty acids, or polyethylene glycols, which are solid at ordinary temperatures but liquid at the rectal temperature, and which will therefore melt in the rectum and release the drug.
  • a suitable non-irritating excipient such as cocoa butter, synthetic mono-, di-, or triglycerides, fatty acids, or polyethylene glycols, which are solid at ordinary temperatures but liquid at the rectal temperature, and which will therefore melt in the rectum and release the drug.
  • Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules.
  • the compounds are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration.
  • the compounds can be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration.
  • Such capsules or tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose.
  • the dosage forms can also comprise buffering agents such as sodium citrate, or magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings.
  • formulations for parenteral administration can be in the form of aqueous or non- aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions can be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration.
  • Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water.
  • Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents .
  • the amount of active ingredient that can be combined with the carrier materials to produce a single dosage of the MCH receptor antagonist will vary depending upon the patient and the particular mode of administration.
  • the pharmaceutical compositions may contain an MCH receptor antagonist in the range of about 1 to about 250 mg, more typically, in the range of about 10 to about 200 mg and still more typically, between about 25 to about 150 mg.
  • a daily dose of about 0.01 to about 80 mg/kg body weight, or more typically, between about 0.5 to about 50 mg/kg body weight and even more typically, from about 1 to about 25 mg/kg body weight, may be appropriate.
  • the daily dose can be administered in one to about four doses per day.
  • the MCH receptor antagonists are administered in such amount as will be therapeutically effective in the treatment or control of the disorder or condition being treated. It will be appreciated that the amount of active ingredients contained in an individual dose of each dosage form need not in itself constitute an effective amount, as the necessary effective amount could be reached by administration of a number of individual doses. Those skilled in the art will appreciate that the quantity of active MCH receptor antagonist to be administered will vary depending upon the age, sex, and body weight of the subject to be treated, the type of disease, or syndrome to be treated, the particular method and scheduling of administration, and what other MCH receptor antagonist, if any, is co-administered. Dosage amounts for an individual patient may thus be above or below the typical dosage ranges.
  • the MCH receptor antagonist can be employed in any amount known to be effective at treating, preventing or controlling the disorder or condition being treated.
  • the doses may be single doses or multiple doses per day, with the number of doses taken per day and the time allowed between doses varying depending on the individual needs of the patient. Optimization of treatment, including dosage amount, method and time of administration, is thus best determined by a skilled practitioner through close monitoring of patients on an individual basis.
  • dosages may also be determined with guidance from Goodman & Goldman, The Pharmacological Basis of Therapeutics, 9th Ed. (1996) , App. II, pp. 1707-1711 and from Goodman & Goldman, The Pharmacological Basis of Therapeutics, 10th Ed. (2001) , App.
  • the MCH receptor antagonist is a compound of Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, having the following structure :
  • W is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano;
  • X is selected from the group consisting of -OR 1 , -NR ⁇ 10 , and -SR 1 ;
  • Y is selected from the group consisting of hydrogen, -N(R 7 )C(0)NR 2 R 8 , -N(R 7 )C(0)OR 2 , -N (R 7 ) C (O) R 2 , -N(R 7 )S0 2 R 2 , and -NR 2 R 7 ;
  • the MCH receptor antagonist consists of compounds of Formula I, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0120] W is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; [0121] X is selected from the group consisting of -OR 1 , -NR X R 10 , and -SR 1 ; [0122] Y is selected from the group consisting of hydrogen, -N(R 7 )C(0)NR 2 R 8 , -N(R 7 )C(0)OR 2 , -N (R 7 ) C (O) R 2 , -N(R 7 )S0 2 R 2 , and -NR 2 R 7 ; [0123] Z is selected from the group consisting of hydrogen, -
  • the MCH receptor antagonist consists of compounds of Formula I, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0137] W is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxy
  • the MCH receptor antagonist consists of compounds of Formula I, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0188] W is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl , methoxybutyl ,
  • W is selected from the group consisting of hydrogen, hydroxy, alkyl, and alkoxy;
  • X is selected from the group consisting of -OR 1 , -NR 3 ⁇ 10 , and -SR 1 ;
  • Y is selected from the group consisting of hydrogen, -N(R 7 )C(0)NR 2 R 8 , -N(R 7 )C(0)OR 2 , -N (R 7 ) C (O) R 2 , -N(R 7 )S0 2 R 2 , and -NRR 7 ;
  • R 1 is selected from the group consisting of alkyl, cycloalkyl,
  • X is selected from the group consisting of -OR 1 and -SR 1 ;
  • Y is selected from the group consisting of hydrogen, -N(R 7 )C(0)NR 2 R 8 , -N(R 7 )C(0)OR 2 , -N (R 7 ) C (0) R 2 , -N(R 7 )S0 2 R 2 , and -NR 2 R 7 ;
  • R 1 is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R 1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and
  • X is selected from the group consisting of -OR 1 and -SR 1 ;
  • R 1 is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R 1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R 2 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R 2 together with R 8 and the nitrogen to which
  • X is selected from the group consisting of -OR 1 and -SR 1 ;
  • R 1 is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R 1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R 2 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R 2 together with R 8 and the nitrogen to which they are attached
  • R 1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl
  • X is selected from the group consisting of -OR 1 and -SR 1 ;
  • R 1 is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R 1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo;
  • R 2 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R 2 together with R 8 and the nitrogen to which they are attached
  • R 1 is selected from the group consisting of cycloalkyl and aryl, wherein R 1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, and halo
  • R 2 is selected from the group consisting of alkyl, aryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R 2 together with R 8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R 2 or the unsaturated fused heterocyclic ring formed with R 8 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, aryloxy, and halo;
  • R s is selected from the group consisting of hydrogen and alkyl, or R 5 together with R 5 and the nitrogen to which they are attached may form
  • the MCH receptor antagonist consists of compounds of Formula VII, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0417] R 1 is selected from the group consisting of lower cycloalkyl and aryl, wherein R 1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, and halo; [0418] R 2 is selected from the group consisting of lower alkyl, aryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R 2 together with R 8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R 2 or the unsaturated fused heterocyclic ring formed with R 8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, aryl
  • the MCH receptor antagonist consists of compounds of Formula VII, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0423] R 1 is selected from the group consisting of cyclopentyl, cyclohexyl, phenyl, naphthyl, and biphenyl, wherein R 1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, hydroxy, methoxy, ethoxy, propoxy, chloro, bromo, and fluoro; [0424] R 2 is selected from the group consisting of methyl, ethyl, propyl, butyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, phenylethyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cycl
  • the MCH receptor antagonist consists of compounds of Formula VII, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0429] R 1 is selected from the group consisting of phenyl, and naphthyl, wherein R 1 is optionally substituted with one or more substituents selected from the group consisting of methyl, chloro, and fluoro; [0430] R 2 is selected from the group consisting of methyl, ethyl, phenyl, naphthyl, biphenyl, benzyl, phenylethyl, cyclopentylethyl, phenylethenyl, phenylcyclopropyl, or R 2 together with R 8 and the nitrogen to which they are attached may form a dihydroisoindolyl ring, wherein R 2 or the ring formed with R 8 is optionally substituted with one or more substituents selected from the group consisting of methyl, propyl, meth
  • the compound of Formula I is selected from the group of compounds of Formula V having the structure :
  • R 2a , R 2b , R 2c , R , and R 2e are as defined in Table 2 .
  • the compound of Formula I is selected from the group of compounds of Formula V having the structure :
  • R 2a , R 2b , R 2c , R 2d , and R 2e are as defined in Table 2.
  • the compound of Formula I is selected from the group of compounds of Formula V having the structure :
  • R 2a , R 2b , R 2c , R 2 , and R 2e are as defined in Table 2.
  • the compound of Formula I is selected from the group of compounds of Formula V having the structure:
  • R 2a , R b , R 2c , R 2d , and R 2e are as defined in Table 2.
  • the compound of Formula I is selected from the group of compounds of Formula V having the structure :
  • R 2a , R 2b , R 2c , R 2d , and R 2e are as defined in Table 2.
  • the compound of Formula I is selected from the group of compounds of Formula V having the structure :
  • R 2a , R 2b , R 2c , R 2d , and R 2e are as defined in Table 2 .
  • the compound of Formula I is selected from the group of compounds of Formula V having the structure :
  • R 2a , R , R 2c , R 2d , and R 2e are as defined in Table 2.
  • the compound of Formula I is selected from the group of compounds of Formula V having the structure :
  • R 2a , R 2b , R 2c , R 2d , and R 2e are as defined in Table 2.
  • the compound of Formula I is selected from the group of compounds of Formula V having the structure :
  • R , R 2b , R 2c , R 2d , and R 2e are as defined in Table 2.
  • the compound of Formula I is selected from the group of compounds of Formula V having the structure :
  • R 2a , R 2b , R 2c , R d , and R 2e are as defined in Table 2.
  • the compound of Formula I is selected from the group of compounds of Formula V having the structure :
  • R 2 , R 2b , R 2c , R , and R 2e are as defined in Table 2.
  • the compound of Formula I is selected from the group of compounds of Formula V having the structure : [0458] wherein R 2a , R b , R 2c , R 2d , and R 2e are as defined in Table 2.
  • the compound of Formula I is selected from the group of compounds of Formula V having the structure :
  • R 2a , R 2b , R 2c , R 2d , and R 2e are as defined in Table 2.
  • the compound of Formula I is selected from the group of compounds of Formula V having the structure :
  • the compound of Formula I is selected from the group of compounds of Formula V having the structure :
  • R , R 2 , R , R , and R 2e are as defined in Table 2.
  • the compound of Formula I is selected from the group of compounds of Formula V having the structure :
  • R 2a , R 2b , R 2c , R 2d , and R 2e are as defined in Table 2.
  • the compounds of Formula I are MCH receptor antagonists, as demonstrated by the ligand binding assays described hereinbelow. MCH receptor antagonist activity has been correlated with pharmaceutical activity for the treatment of eating disorders such as obesity and hyperphagia, and diabetes. Compounds of Formula I exhibit good activity in standard in vitro MCH calcium mobilization assays and/or receptor binding assays, specifically in the assays described hereinbelow, see Examples 23 and 24. Generally, compounds of Formula I have an Kj.
  • MCH receptor antagonists of Formula I are MCH receptor antagonists and exhibit IC 50 values of about 10 ⁇ M or less, preferably about 1 ⁇ M or less, more preferably about 100 nM or less, or even more preferably about 10 nM or less, as determined by a standard in vi tro MCH receptor binding assay such as is described hereinbelow in Example 24.
  • the MCH receptor antagonists of Formula I bind specifically, and still more preferably with high affinity, to MCH receptors.
  • Method 1 [0474] Starting material (10 mg, 0.021 mmol) was combined with 1,2-dibromoethane (2.3 ⁇ L, 0.025 mmol) and NaH (1 mg, 0.042 mmol) in 0.5 mL DMF at room temperature. The mixture was then heated to 80 °C for 1 hour. The reaction mixture was worked up with water and EtOAc . Method 2 [0475] Starting material (20 mg, 0.04 mmol) was combined with 1,2-diiodoethane (14.3 mg, 0.05 mmol) and NaH (2 mg, 0.08 mmol) in 0.5 mL DMF, then reacted as described above.
  • Human embryonic kidney cells (293 total) expressing either human, rat, or mouse MCH receptor were harvested from 150 mm culture dishes using PBS. Spinning at 1500 rpm for 2 minutes initially pelleted cells. The resulting pellet was then homogenized in 15 mL ice cold sucrose buffer (25 mM HEPES, 0.3 M sucrose, pH 7.4) with a motorized, glass fitted, Teflon ® homogenizer.
  • the homogenate was centrifuged at 48,000 X g at 4°C for 10 minutes, resuspended in 15 mL assay buffer (25 mM HEPES, 10 mM MgCl 2 , 0.2% BSA, 0.1 mg/mL STI, 0.1 mg/mL Pefabloc ® , 1 ⁇ M Phosphoramidon, pH 7.4) with a Tissue-Tearor ® (Biospec Products) and centrifuged again at 48,000 X g for 10 minutes. The pellet was homogenized for a third time in 15 mL assay buffer using the Tissue-Tearor ® and again centrifuged at 48,000 X g for 10 minutes.
  • 15 mL assay buffer 25 mM HEPES, 10 mM MgCl 2 , 0.2% BSA, 0.1 mg/mL STI, 0.1 mg/mL Pefabloc ® , 1 ⁇ M Phosphoramidon, pH 7.4
  • HT-PS100 Protocol [0486] Materials: HEK 293 cells were stably transfected with the rat MCH 1 receptor and maintained under G418 antibiotic pressure.
  • HT-PS100 assay buffer consisted of Physiological Saline Solution (145 mM NaCl, 5.4 mM KCL, 1.0 mM NaH 2 P0 4 , 1.8 mM CaCl 2 , 0.8 mM MgS0 4 , 15.0 mM HEPES, pH 7.4, 11.2 mM glucose) + 50 ⁇ M Pluronic-F127.
  • MCH peptide Amgen, Inc.
  • Test compounds were prepared as 10 mM stocks in 100% DMSO and diluted to a top end working concentration of 100 ⁇ M in 96 well plates.
  • Methods HEK 293 stably expressing MCH1R were maintained in Dulbeco's modified Eagle's medium (GIBCO/Life Technologies, Rockville, MD) supplemented with 2 mM glutamine and 10% dialyzed fetal bovine serum (HyClone, Logan, UT) at 37°C, 5% C0 2 .
  • Cells were harvested by 10' treatment with Versene (GIBCO/Life Technologies) followed by trituration, washing twice with cold (4°C) hybridoma medium (Serum/Protein free, with L- glutamine, sodium bicarbonate, MOPS buffer) (Sigma-Aldrich Corp, St. Louis, MO) and resuspended at 2 x 106 cells/mL in the same medium.
  • the resuspended cells were loaded with the fluorescent calcium indicator Fura-2 by incubating with Fura-2AM (Molecular Probes, Eugene, OR) at 1.6 ⁇ M for 60' at room temperature.
  • Antagonist activity was tested by 30 s pre-incubation of cells at a compound concentration of 100 ⁇ M, with subsequent introduction of MCH at a concentration 5-fold of EC 50 as determined in preliminary experiments. Compounds that showed inhibition of the MCH-induced Ca ++ response were automatically tagged for re-interrogation, IC 50 generation, and Schild analysis. [0491] Schild experiments were conducted on the HT-PS100 for selected compounds by 30 s pre-incubation of cells with antagonist compounds prior to administering MCH peptide. Several fixed concentrations of antagonist compounds were prepared in 10-fold increments, and presented to the cells 30 s before introducing a gradient of increasing MCH concentration.
  • FLIPR ® protocol [0493] Materials: Pharmacological analysis was conducted using a FLIPR ® device (Molecular Devices, Sunnyvale, CA) . CHOK1- Gqi cells were stably transfected with the rat MCHl receptor and maintained under G418 antibiotic pressure. FLIPR ® assay buffer consisted of phenol red-free DMEM + 2.5 mM probenecid. MCH peptide (Amgen, Inc.) was reconstituted in assay buffer and served as the positive agonist control for all experiments.
  • Test compounds were prepared as 10 mM stocks in 100% DMSO and diluted to a top end working concentration of 10 ⁇ M in 96 well black, flat bottom, collagen-I coated plates (Becton Dickinson, Bedford, MA) .
  • Methods CHOKl-Gqi cells stably expressing MCH1R were maintained in Dulbeco's modified Eagle's medium (GIBCO/Life Technologies, Rockville, MD) supplemented with 2 mM glutamine and 10% dialyzed fetal bovine serum (HyClone, Logan, UT) at 37 °C, 5% C0 2 .
  • Cells were harvested by 10' treatment with Versene (GIBCO/Life Technologies) followed by trituration, washing twice with cold (4°C) hybridoma medium (Serum/Protein free, with L- glutamine, sodium bicarbonate, MOPS buffer) (Sigma-Aldrich Corp, St. * Louis, MO) and replated onto 96 well black, flat bottom, collagen-I coated plates to a density of 10,000 cells/well.
  • the cells were then loaded with the fluorescent calcium indicator Fura-2 (Molecular Probes, Eugene, OR) at 1.6 ⁇ M for 60' at room temperature.
  • the loaded cells were then washed twice with 90 ⁇ l/well of wash buffer (1XHBSS, 20 mM HEPES, 2.5 mM probenecid) .
  • Receptor-stimulated intracellular calcium responses were detected using FLIPR ® by monitoring increases in the Fura-2 fluorescence response.
  • Test compounds were screened for MCH1R activity in the FLIPR ® for both agonist and antagonist action. Agonist mode challenges were conducted at a maximum gradient concentration of 1 ⁇ M. Antagonist activity was tested by 10 min pre-incubation of cells at a compound concentration of defined to be 300X the EC 50 of MCH (typically 1 ⁇ M) , with subsequent introduction of MCH at a concentration 5-fold of EC 50 as determined in preliminary experiments.
  • Compound Nos. 1, 6, 15, 31, 32, 38, 39, 40, and 41 had Ki values of 100 nM or less in this assay.
  • the following compounds had Ki values of 100 ⁇ M or less in the hMCH FLIPR ® assay: Compound Nos. 1, 5, 6, 34, 35, 36, 37, 38, 40, 41, 51, 52, 53, 54, 55, 56, 57, 58, 59, and 64.
  • Compound Nos. 1, 6, 34, 35, 38, 40, 41, 51, 56, and 57 had Ki values of 100 nM or less in this assay.
  • Binding assays were determined as described below using mouse, rat or human MCH 1 receptors (mMCHlR, rMCHIR, and hMCHIR, respectively) expressed in HEK 293; IC 50 values were calculated. [0501] Binding assays were performed in 96-well U-bottom plates. Membranes (100 ⁇ g tissue) were incubated at 30°C for 90 minutes in assay buffer with various peptides in the presence of 0.2 nM 1251 native-MCH (Perkin-Elmer Life Sciences, Boston, MA) in 100 ⁇ L total volume. Non-specific binding was assessed in the presence of 1 ⁇ M cold native-MCH.
  • Compound Nos. 1, 31, 38, 39, 40, 41, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 63, 64, 65, and 66 had IC 50 values of 100 nM or less in the rMCH assay.
  • the following compounds had IC 50 values of 100 ⁇ M or less in the hMCH assay: Compound Nos.

Abstract

Novel compounds, or pharmaceutically-acceptable salts, tautomers or prodrugs thereof, of Formula (I) (I) wherein W, X, Y, Z, R3-R6 , and R11 are as defined in the specification, are provided. Also provided are methods of treating or preventing a melanin concentrating hormone-mediated disorder in a subject, comprising administering to a subject in need of such treatment or prevention a compound of Formula I.

Description

MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS
Background of the Invention [0001] In 1999, 61% of adults, 13% of children aged 6 to 11 years and 14% of adolescents aged 12 to 19 years in the United States were overweight . Increases in occurrence of overweight and obesity has been seen in all age, racial and ethnic groups, and in both men and women. [0002] Epidemiological studies show an increase in mortality associated with overweight and obesity. Individuals who are obese (body mass index ("BMI") > 30) have a 50-100% increased risk of premature death from all causes compared to individuals with a BMI in the range of 20 to 25. BMI is calculated according to the formula: Weight in pounds BMI = — (-H—ei rg-hr—t—m. i:nc:hes r)τ~ X 703 [0003] An estimated 300,000 deaths a year in the United States may be attributable to obesity. Overweight and obesity are associated with an increased risk for coronary heart disease; type 2 diabetes; endometrial, colon, postmenopausal breast, and other cancers; and certain musculoskeletal disorders, such as knee osteoarthritis. [0004] Both modest and large weight gains are associated with significantly increased risk of disease. For example, a weight gain of 11 to 18 pounds increases a person's risk of developing type 2 diabetes to twice that of individuals who have not gained weight, while those who gain 44 pounds or more have four times the risk of type 2 diabetes. A gain of approximately 10 to 20 pounds results in an increased risk of coronary heart disease (nonfatal myocardial infarction and death) of 1.25 times in women and 1.6 times in men. Higher levels of body weight gain of 22 pounds in men and 44 pounds in women result in an increased coronary heart disease risk of 1.75 and 2.65, respectively. In women with a BMI of 34 or greater, the risk of developing endometrial cancer is increased by more than six times. Overweight and obesity are also known to exacerbate many chronic conditions such as hypertension and elevated cholesterol. Overweight and obese individuals also may suffer from social stigmatization, discrimination, and poor body image. Although obesity-associated morbidities occur most frequently in adults, important consequences of excess weight as well as antecedents of adult disease occur in overweight children and adolescents. Overweight children and adolescents are more likely to become overweight or obese adults; this concern is greatest among adolescents. Type 2 diabetes, high blood lipids, and hypertension as well as early maturation and orthopedic problems also occur with increased frequency in overweight youth. A common consequence of childhood overweight is psychosocial— specifically discrimination. See The Surgeon General's Call To Action To Prevent and Decrease Overweight and Obesity, U.S. Dept . of Health and Human Services, 2001. Thus, the need exists for methods of controlling weight and treating obesity. [0005] Melanin-concentrating hormone (MCH) is a cyclic, 19- amino acid hypothalamic neuropeptide derived from a larger pro- hormone precursor of MCH, P ch. Pmch-deficient mice are lean, hypophagic, and have an increased metabolic rate. Transgenic mice over-expressing Pmch are hyperphagic and develop mild obesity. Consequently, MCH has been implicated in the regulation of energy homeostasis, through actions on motor activity, metabolism, food intake and neuroendocrine function. [0006] Two receptors have been identified in MCH, and are designated MCH 1 receptor and MCH 2 receptor. The MCH 1 and MCH 2 receptors are G protein-coupled receptors (GPCRs) believed to be responsible for the actions of MCH. G proteins are heterotrimeric proteins that control cellular responses to stimuli by cycling between a GTP-bound active state, which regulates the activity of a number of effector proteins, and a GDP-bound inactive state. GPCRs accelerate activation of the G protein by increasing the GDP/GTP exchange rate.. [0007] MCH 1 receptor-deficient mice have normal body weights, yet are lean and have reduced fat mass. Surprisingly, MCH 1 receptor-deficient mice are hyperphagic when maintained on regular chow, and their leanness is a consequence of hyperactivity and altered metabolism. Consistent with the hyperactivity, MCH 1 receptor-deficient mice are less susceptible to diet-induced obesity. Importantly, chronic central infusions of MCH induce hyperphagia and mild obesity in wild-type mice, but not in MCH 1 receptor-deficient mice. Marsh et al., Proc. Nat. Acad. Sci., 99(5), 3241 (2002). [0008] Because MCH has been shown to be an important regulator of food intake and energy balance, compounds capable of modulating the activity of MCH receptors, particularly MCH 1 receptors, are highly desirable for the treatment of eating disorders and metabolic disorders . [0009] PCT Publication No. WO 02/04433 describes phenylcycloalkylmethylamino and phenylalkenylamino derivatives as modulators of MCH 1 receptors useful in the treatment of certain metabolic, feeding and sexual disorders. [0010] U.S. Patent No. 6,472,394 describes the use of amide derivatives of 1, 4-disubstituted piperidine as MCH antagonists for the treatment of obesity and diabetes.
Summary of the Invention [0011] Among the several objects of certain embodiments of the present invention, therefore, may be noted the provision of melanin concentrating hormone receptor antagonists; the provision of pharmaceutical compositions comprising melanin concentrating hormone receptor antagonists; the provision of methods of treating, preventing, or otherwise ameliorating melanin concentrating hormone-mediated disorders in a subject; the provision of methods for treating, preventing or otherwise ameliorating obesity in a subject; and the provision of methods of achieving sustained body weight loss in a subject. [0012] Briefly therefore, the present invention is directed to a melanin concentrating hormone receptor antagonist of Formula I as defined herein. [0013] The present invention is also directed to pharmaceutical compositions comprising a compound of Formula I, as defined herein, and a pharmaceutically acceptable carrier, adjuvant, or diluent. [0014] The present invention is also directed to a method of inhibiting a GPCR, comprising contacting a compound of Formula I, as defined herein, with a GPCR, wherein the compound of Formula I is present at a concentration sufficient to inhibit the binding of a GPCR ligand in vi tro . This method includes inhibiting a GPCR in vivo, e.g., in a subject given an amount of a compound of Formula I that would be sufficient to inhibit the binding of a ligand to the GCPR in vi tro . Examples of GPCRs which may be inhibited according to the present invention include, but are not limited to the following GPCR families: Acetylcholine muscarinic, Adenosine, adrenergic, adrenergic, alpha-adrenergic, angiotensin, AR, Cannabinoid, DA, dopamine, His, imidazoline, Leukotriene, mAch, MCH, Opioid, serotonergic, serotonin, and Somatostatin. [0015] Inhibition of the binding of a GPCR ligand to GPCRs is useful in the treatment of numerous disorders, including digestive tract disorders; mucolytic asthma; arrhythmia; ischemia; reperfusion injury; bronchospasm associated with asthma, emphysema and chronic bronchitis; acute and chronic respiratory diseases, including cystic fibrosis; cardiostimulant ; chronic bronchitis; neurological depression; heart failure; benign prostate hypertrophy; diabetes; muscle spasm; myocardial infarction; stroke; Alzheimer's disease; anorexia; cachexia; multiple sclerosis; hyperprolactinemia; psychotropism; mydriasis in ocular examination and surgery; deficitary and productive schizophrenia, psychasthenia and non- endogenous depression; kidney disease; vasodilation; chronic gastritis; glaucoma; depression; rhinitis, including allergic rhinitis; pain, including cancer pain, musculoskeletal pain, post-operative pain; eye disease; dyspepsia; cough; ulcer, including gastrointestinal, gastric and esophageal ulcers; helicobacter pylori prophylaxis infection; oesophagitis; allergies, including non-asthma allergies; cold; asthma; conjuctivitis; urticaria; diarrhea; Creutzfeldt-Jakob disease; dysmenorrhoea; drug addiction and drug overdose; septic shock treatment; cerebral ischaemia; drug posoning; head trauma,- inflammation; pruritus; tardive dyskinesia; emesis; anxiety; motility dysfunction; cluster headaches; hypertension; cancer; irritable bowel syndrome; hemotherapy-induced nausea and vomiting; thrombosis; dementia; opiate-induced nausea and vomiting; bipolar depression; migraine; sleep disorders; traumatic shock; gastritis; gastro-oesophageal reflux; psychosis; Parkinson disease; Dependence treatment; Pre- eclampsia; Raynaud's disease; Vasospasm; haemostasis; nausea and vomiting; spasms; post-operative nausea and vomiting; alcoholism, alcohol addiction; bulimia; nicotine addiction; obsessive-compulsive disorder; panic disorder; post-traumatic stress disorder; premenstrual syndrome; and dermatitis, including allergic dermatitis. [0016] The present invention is also directed to methods of inhibiting the binding of MCH to MCH receptors comprising contacting a compound of Formula I with cells expressing MCH receptors, wherein the compound is present at a concentration sufficient to inhibit MCH binding to MCH receptors in vitro. This method includes inhibiting the binding of MCH to MCH receptors in vivo, e.g., in a subject given an amount of a compound of Formula I that would be sufficient to inhibit the binding of MCH to the MCH receptors in vi tro. The amount of a compound of Formula I that would be sufficient to inhibit the binding of MCH to the MCH receptor in vi tro may be readily determined via a MCH receptor binding assay, such as the assay described hereinbelow in Example 24. [0017] The present invention is also directed to methods for altering the signal-transducing activity of MCH receptors, particularly the MCH receptor-mediated release of intracellular calcium, said method comprising exposing cells expressing such receptors to an effective amount of a compound of the invention. This method includes altering the signal-transducing activity of MCH receptors in vivo, e.g., in a subject given an amount of a compound of Formula I that would be sufficient to alter the signal-transducing activity of MCH receptors in vi tro . The amount of a compound that would be sufficient to alter the signal-transducing activity of MCH receptors may be determined via a MCH receptor signal transduction assay, such as the calcium mobilization assay described hereinbelow in Example 23. [0018] The present invention is also directed to methods of using compounds of Formula I and appropriately labeled derivatives thereof as standards and reagents in determining the ability of a potential pharmaceutical to bind to MCH receptor. [0019] The present invention is also directed to methods of treating, preventing, or otherwise ameliorating melanin concentrating hormone-mediated disorders in a subject, the method comprising administering a compound of Formula I or a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically-acceptable carrier, adjuvant, or diluent to said subject. [0020] The present invention is also directed to methods of treating or preventing obesity in a subject, the method comprising administering a compound of Formula I or a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically-acceptable carrier, adjuvant, or diluent to said subject. [0021] The present invention is also directed to methods of treating or preventing conditions such as feeding disorders, including obesity, bulimia and bulimia nervosa; sexual or reproductive disorders; depression and anxiety; epileptic seizure; hypertension; cerebral hemorrhage; congestive heart failure; sleep disturbances; or any condition in which antagonism of an MCH receptor is beneficial . [0022] The present invention is also directed to methods of treating eating disorders, particularly obesity and bulimia nervosa, comprising administering to a subject in need of such treatment a compound of Formula I in combination with leptin, a leptin receptor agonist, or a melanocortin receptor 4 (MC4) agonist . [0023] The present invention is also directed to methods of using compounds of Formula I as positive controls in assays for activity of GPCRs, particularly MCH. [0024] The present invention is also directed to methods of using appropriately labeled compounds of Formula I as probes for the localization of GPCRs, particularly MCH, in tissue sections. [0025] Other objects and features will be in part apparent and in part pointed out hereinafter.
Abbreviations and Definitions [0026] The term "alkyl", where used alone or within other terms such as "haloalkyl", "alkylsulfonyl" , "alkoxyalkyl" and "hydroxyalkyl", is a linear or branched radical having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are "lower alkyl" radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, sec- butyl, and tert-butyl) , pentyl (e.g., n-pentyl and iso-amyl) , hexyl, and the like. [0027] The term "cycloalkyl" is a saturated carbocyclic radical having three to twelve carbon atoms. The cycloalkyl radical may be mono-, bi-, or tricyclic. More preferred cycloalkyl radicals are "lower cycloalkyl" radicals having three to about eight carbon atoms. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. [0028] The term "alkenyl" is a linear or branched radical having at least one carbon-carbon double bond and having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkyl radicals are "lower alkenyl" radicals having two to about six carbon atoms. Examples of alkenyl radicals include ethenyl, propenyl, allyl, butenyl and 4-methylbutenyl . The terms "alkenyl" and "lower alkenyl" also are radicals having "cis" and "trans" orientations, or alternatively, "E" and "Z" orientations. [0029] The term "cycloalkenyl" is a partially unsaturated carbocyclic radical having three to twelve carbon atoms. The cycloalkenyl radicals may be mono-, bi-, or tricyclic. More preferred cycloalkenyl radicals are "lower cycloalkenyl" radicals having four to about eight carbon atoms. Examples of such radicals include cyclobutenyl, cyclopentenyl, cyclopentadienyl, and cyclohexenyl . [0030] The term "alkynyl" is a linear or branched radical having at least one carbon-carbon triple bond and having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkynyl radicals are "lower alkynyl" radicals having two to about ten carbon atoms. Most preferred are lower alkynyl radicals having two to about six carbon atoms. Examples of such radicals include propargyl, butynyl, and the like. [0031] The terms "carboxy" or "carboxyl", whether used alone or with other terms, such as "carboxyalkyl" , is -C02H. [0032] The term "carboxyalkyl" is an alkyl radical as defined above substituted with a carboxy radical. More preferred are "lower carboxyalkyl" radicals, which are lower alkyl radicals as defined above substituted with a carboxy radical, and may be additionally substituted on the alkyl radical with halo. Examples of such lower carboxyalkyl radicals include carboxymethyl , carboxyethyl and carboxypropyl . [0033] The term "halo" is a halogen such as fluorine, chlorine, bromine or iodine. [0034] The term "haloalkyl" is an alkyl radical as defined above wherein any one or more of the carbon atoms is substituted with halo as defined above. Specifically included are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. More preferred haloalkyl radicals are "lower haloalkyl" having one to six carbon atoms. Examples of lower haloalkyl radicals include fluoromethyl , difluoromethyl, trifluoromethyl, chlorαmethyl, dichloromethyl, trichloromethyl , trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl , difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl . [0035] The terms "alkoxy" and "alkyloxy" are linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are "lower alkoxy" radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy. The "alkoxy" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy radicals. More preferred haloalkoxy radicals are "lower haloalkoxy" radicals having one to six carbon atoms and one or more halo radicals. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and fluoropropoxy. [0036] The term "alkoxyalkyl" is an alkyl radical having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and polyalkoxyalkyl radicals. More preferred alkoxyalkyl radicals are "lower alkoxyalkyl" radicals having two to twelve carbon atoms. Examples of such radicals include methoxymethyl , methoxyethyl , methoxypropyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , dimethoxymethyl , dimethoxyethyl , methoxy (ethoxy) ethyl, dimethoxypropyl , and methoxy (ethoxy) propyl . [0037] The term "alkoxycarbonyl" is a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a carbonyl radical, i.e., an ester radical. More preferred are "lower alkoxycarbonyl" radicals with alkyl portions having one to six carbons. Examples of such lower alkoxycarbonyl radicals include substituted or unsubstituted methoxycarbonyl , ethoxycarbonyl , propoxycarbonyl , butoxycarbonyl and hexyloxycarbonyl . [0038] The term "hydroxyalkyl" is a linear or branched alkyl radical having one to about ten carbon atoms, any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are "lower hydroxyalkyl" radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl and hydroxyhexyl . [0039] The term "alkylamino" is an amino group that has been substituted with one or two alkyl radicals. Preferred are "lower N-alkylamino" radicals having alkyl portions having one to six carbon atoms. Suitable lower alkylamino may be mono- or dialkylamino, such as N-methylamino, N-ethylamino, N,N- dimethylamino, N,N-diethylamino or the like. [0040] The term "alkylaminoalkyl" is a radical having one or more alkyl radicals attached to the nitrogen atom of an aminoalkyl radical . [0041] The term "alkylaminocarbonyl" is an aminocarbonyl group that has been substituted with one or two alkyl radicals on the amino nitrogen atom. Preferred are "N-alkylaminocarbonyl" "N,N-dialkylaminocarbonyl" radicals. More preferred are "lower N-alkylaminocarbonyl" and "lower N,N-dialkylaminocarbonyl" radicals with lower alkyl portions as defined above. [0042] The term "alkylthio" is a radical containing an alkyl radical of one to about ten carbon atoms attached to a divalent sulfur atom. More preferred alkylthio radicals are "lower alkylthio" radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthio radicals are methylthio, ethylthio, propylthio, butylthio and hexylthio. [0043] The term "alkylthioalkyl" is a radical containing an alkylthio radical attached through the divalent sulfur atom to an alkyl radical of one to about ten carbon atoms . More preferred alkylthioalkyl radicals are "lower alkylthioalkyl" radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthioalkyl radicals include methylthiomethyl, methylthioethyl, ethylthioethyl, and ethylthiopropyl . [0044] The term "alkylsulfinyl" is a radical containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent -S (=0) - radical. More preferred alkylsulfinyl radicals are "lower alkylsulfinyl" radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylsulfinyl radicals include methylsulfinyl, ethylsulfinyl, butylsulfinyl and hexylsulfinyl . [0045] The term "aminoalkyl" is an alkyl radical substituted with one or more amino radicals. More preferred are "lower aminoalkyl" radicals of one to six carbon atoms. Examples of such radicals include aminomethyl, aminoethyl, and the like. [0046] The term "aminocarbonyl" is an amide group of the formula -C(=0)NH2. [0047] The term "carbonyl", whether used alone or with other terms, such as "alkoxycarbonyl", is - (C=0) - . [0048] The term "aryl", alone or in combination, is a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused, and wherein at least one of the rings is aromatic. The term "aryl" includes aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl. Aryl moieties may also be substituted at a substitutable position with one or more substituents selected independently from alkyl, alkoxyalkyl, alkylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, a inocarbonylalkyl , alkoxy, aralkoxy, hydroxyl, amino, halo, nitro, alkylamino, acyl, cyano, carboxy, aminocarbonyl, alkoxycarbonyl and aralkoxycarbonyl . [0049] The terms "heterocyclyl" and "heterocyclo" are saturated or partially unsaturated heteroatom-containing ring- shaped radicals having one, two, or three rings wherein such rings may be attached together in a pendent manner or may be fused, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. Examples of saturated heterocyclyl and heterocyclo radicals include saturated 3- to 6-membered heteromonocylic radicals containing one to four nitrogen atoms (e.g., pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.); saturated 3- to 6-membered heteromonocyclic group containing one to two oxygen atoms and one to three nitrogen atoms (e.g., morpholinyl, etc.); saturated 3- to 6-membered heteromonocyclic group containing one to two sulfur atoms and one to three nitrogen atoms (e.g., thiazolidinyl, etc.). Examples of partially unsaturated heterocyclyl and heterocyclo radicals include dihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole. [0050] The term "heteroaryl" is an aromatic heteroatom- containing ring-shaped radical having one, two, or three rings wherein at least one ring is aromatic. Examples of heteroaryl radicals include unsaturated 3- to 6- membered heteromonocyclic group containing one to four nitrogen atoms, e.g., pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1, 2 , 4-triazolyl, 1H- 1,2, 3 -triazolyl, 2H-1, 2 , 3 -triazolyl , etc.) tetrazolyl (e.g. 1H- tetrazolyl, 2H-tetrazolyl, etc.), etc.; unsaturated condensed heterocyclyl group containing one to five nitrogen atoms, e.g., indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl (e.g., tetrazolo [1, 5-b] pyridazinyl , etc.), etc.; unsaturated 3- to 6-membered heteromonocyclic group containing an oxygen atom, e - <3 - r pyranyl, furyl, etc.; unsaturated 3- to 6-membered heteromonocyclic group containing a sulfur atom, e.g., thienyl, etc.; unsaturated 3- to 6-membered heteromonocyclic group containing one to two oxygen atoms and one to three nitrogen atoms, e.g., oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4- oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl , etc.) etc.; unsaturated condensed heterocyclyl group containing one to two oxygen atoms and one to three nitrogen atoms (e.g., benzoxazolyl , benzoxadiazolyl, etc.); unsaturated 3- to 6- membered heteromonocyclic group containing one to two sulfur atoms and one to three nitrogen atoms, e.g., thiazolyl, thiadiazolyl (e.g., 1, 2 , 4 -thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2 , 5-thiadiazolyl , etc.) etc.; unsaturated condensed heterocyclyl group containing one to two sulfur atoms and one to three nitrogen atoms (e.g., benzothiazolyl, benzothiadiazolyl, etc.) and the like. The term "heteroaryl" also includes radicals where heteroaryl radicals are fused with aryl radicals. Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like. Said heterocyclyl group may be substituted at a substitutable position with one or more substituents selected independently from alkyl, hydroxyl, halo, alkoxy, oxo, amino and alkylamino. [0051] The terms "heterocyclylalkyl" and "heterocycloalkyl" are saturated and partially unsaturated heterocyclyl-substituted alkyl radicals, such as pyrrolidinylmethyl, and heteroaryl- substituted alkyl radicals, such as pyridylmethyl , quinolylmethyl , thienylmethyl , furylethyl, and quinolylethyl . The heteroaryl in said heteroaralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy. [0052] The term "acyl" is a radical provided by the residue after removal of hydroxyl from an organic acid. Examples of such acyl radicals include alkanoyl and aroyl radicals. [0053] The term "alkanoyl" or "alkylcarbonyl" are alkyl radicals as defined herein attached to a carbonyl radical. Examples of such alkanoyl radicals include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl , and trifluoroacetyl . [0054] The terms "arylcarbonyl" (also called "aroyl") and "aralkylcarbonyl" include radicals having aryl or aralkyl radicals, as defined herein, attached to a carbonyl radical. Examples of such radicals include substituted or unsubstituted phenylcarbonyl, naththoyl, and benzylcarbonyl . The aryl in said aroyl and aralkylcarbonyl radicals may be additionally substituted. [0055] The term "aralkoxy" is an aralkyl radical as defined herein attached through an oxygen atom to other radicals. [0056] The term "aralkoxyalkyl" is an aralkoxy radical as defined herein attached through an oxygen atom to an alkyl radical . [0057] The terms "aralkyl" and "arylalkyl" are aryl- substituted alkyl radicals such as benzyl, diphenylmethyl , triphenylmethyl , phenylethyl, and diphenylethyl . The aryl in said aralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy. The terms benzyl and phenylmethyl are interchangeable . [0058] The term "aralkylamino" is an aralkyl radical as defined herein attached through an amino nitrogen atom to other radicals. The terms "N-arylaminoalkyl" and "N-aryl-N-alkyl- aminoalkyl" are amino groups which have been substituted with one aryl radical or one aryl and one alkyl radical, respectively, and having the amino group attached to an alkyl radical. Examples of such radicals include N-phenylaminomethyl and N-phenyl-N-methylaminomethyl . [0059] The term "aralkylthio" is an aralkyl radical attached to a sulfur atom. [0060] The term "aralkylthioalkyl" is an aralkylthio radical attached through a sulfur atom to an alkyl radical. [0061] The term "arylamino" is an amino group that has been substituted with one or two aryl radicals. An example of such arylamino radicals is N-phenylamino . The "arylamino" radicals may be further substituted on the aryl ring portion of the radical . [0062] The term "aryloxyalkyl" is a radical having an aryl radical attached to an alkyl radical through a divalent oxygen atom. [0063] The term "arylthioalkyl" is a radical having an aryl radical attached to an alkyl radical through a divalent sulfur atom. [0064] The term "sulfonyl", whether used alone or linked to other terms such as alkylsulfonyl, is a divalent -S02- radical. [0065] The term "alkylsulfonyl" is an alkyl radical attached to a sulfonyl radical, where alkyl is defined as above. More preferred alkylsulfonyl radicals are "lower alkylsulfonyl" radicals having one to six carbon atoms. Examples of such lower alkylsulfonyl radicals include methylsulfonyl, ethylsulfonyl and propylsulfonyl . The "alkylsulfonyl" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkylsulfonyl radicals. [0066] The terms "sulfamyl", "aminosulfonyl" and "sulfonamidyl" are -S02NH2. [0067] The term "pharmaceutically acceptable" is used adjectivally herein to mean that the modified noun is appropriate for use in a pharmaceutical product; that is the "pharmaceutically-acceptable" material is relatively safe and/or non-toxic, though not necessarily providing a separable therapeutic benefit by itself. Pharmaceutically-acceptable cations include metallic ions and organic ions. More preferred metallic ions include, but are not limited to, appropriate alkali metal salts, alkaline earth metal salts and other physiologically-acceptable metal ions. Exemplary ions include aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, in their usual valences. Preferred organic ions include protonated tertiary amines and quaternary ammonium cations, including in part, trimethylamine, diethylamine, N,N'- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. Exemplary pharmaceutically acceptable acids include without limitation hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulfonic acid, acetic acid, formic acid, tartaric acid, maleic acid, malic acid, citric acid, isocitric acid, succinic acid, lactic acid, gluconic acid, glucuronic acid, pyruvic acid, oxalacetic acid, fumaric acid, propionic acid, aspartic acid, glutamic acid, benzoic acid, and the like. [0068] The term "prodrug" refers to a chemical compound that can be converted into a therapeutic compound by metabolic or simple chemical processes within the body of the subject. [0069] The term "subject" for purposes of treatment or prevention includes any human or animal subject who is in need of treatment. The subject can be a domestic livestock species, a laboratory animal species, a zoo animal or a companion animal. In one embodiment, the subject is a mammal. In another embodiment, the mammal is a human being. [0070] The term "PBS" stands for phosphate buffered saline. [0071] The term "HEPES" stands for N-2- hydroxyethylpiperazine-N' -2-ethanesulfonic acid. [0072] The term "BSA" stands for bovine serum albumin. [0073] The term "STI" stands for soybean trypsin inhibitor. [0074] The term "Pefabloc" stands for (4- (2- aminoethyl) benzenesulfonylfluoride, HCl salt. [0075] The term "Phosphoramidon" stands for N-α-L- rhamnopyranosyloxy (hydroxyphosphinyl) -L-leucyl-L-tryptophan. [0076] The term "FCC" stands for flash column chromatography. [0077] The term "Ki" stands for inhibitory rate constant. [0078] The term "FLIPR" stands for fluorometric imaging plate reader. [0079] The term "HEK 293" stands for the human embryonic kidney 293 cell line. [0080] The term "Boc" stands for tert-butoxycarbonyl . [0081] The term "DIG" stands for diisopropylcarbodiimide . [0082] The term "DCM" stands for dichloromethane. [0083] The term "DBU" stands for 1,8- diazabicyclo [5.4.0] undec-7-ene . [0084] The term "phosgene" stands for COCl2. [0085] The term "DCE" stands for dichloroethane. [0086] The term "DMF" stands for dimethylformamide . [0087] The term "EtOAc" stands for ethyl acetate. [0088] The term "HOBt" stands for 1-Hydroxybenzotriazole hydrate . [0089] The term "MeOH" stands for methanol. [0090] The term "TFA" stands for trifluoroacetic acid. [0091] The MCH receptor antagonists employed in the present invention can exist in tautomeric, geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-geometric isomers, E- and Z-geometric isomers, R- and S-enantiomers, diastereomers, d- and 1-isomers, the racemic mixtures thereof and other mixtures thereof . Pharmaceutically acceptable salts of such tautomeric, geometric or stereoisomeric forms are also included within the invention. The terms "cis" and "trans", as used herein, denote a form of geometric isomerism in which two carbon atoms connected by a double bond and each substituted by a hydrogen and another group, will each have a hydrogen atom on the same side of the double bond ("cis") or on opposite sides of the double bond ("trans") . Some of the compounds described herein contain alkenyl groups, and are meant to include both cis and trans or "E" and "Z" geometric forms. Furthermore, some of the compounds described herein contain one or more stereocenters and are meant to include R, S, and mixtures or R and S forms for each stereocenter present . [0092] The MCH receptor antagonists utilized in the present invention may be in the form of free bases or pharmaceutically- acceptable acid addition salts thereof. The term "pharmaceutically-acceptable salts" are salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt may vary, provided that it is pharmaceutically acceptable. Suitable pharmaceutically- acceptable acid addition salts of compounds for use in the present methods may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic) , methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, algenic," hydroxybutyric, salicylic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of use in the present methods include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) , and procaine. All of these salts may be prepared by conventional means from the corresponding compound by reacting, for example, the appropriate acid or base with the compound of any Formula set forth herein. [0093] The MCH receptor antagonists useful in the practice of the present invention can be formulated into pharmaceutical compositions and administered by any means that will deliver a therapeutically effective dose. Such compositions can be administered orally, parenterally, by inhalation spray, rectally, intradermally, transdermally, or topically, in dosage unit formulations containing conventional nontoxic pharmaceutically-acceptable carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques. Formulation of drugs is discussed in, e.g., Hoover, Remington's Pharmaceutical Sciences, (1975), and Liberman & Lach an, Eds., Pharmaceutical Dosage Forms, (1980) . [0094] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally-acceptable diluent or solvent. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are useful in the preparation of injectables. Dimethyl acetamide, surfactants including ionic and non-ionic detergents, and polyethylene glycols can be used. Mixtures of solvents and wetting agents such as those discussed above are also useful . [0095] Suppositories for rectal administration of the compounds discussed herein can be prepared by mixing the active agent with a suitable non-irritating excipient such as cocoa butter, synthetic mono-, di-, or triglycerides, fatty acids, or polyethylene glycols, which are solid at ordinary temperatures but liquid at the rectal temperature, and which will therefore melt in the rectum and release the drug. [0096] Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds can be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. In the case of capsules, tablets, and pills, the dosage forms can also comprise buffering agents such as sodium citrate, or magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings. [0097] For therapeutic purposes, formulations for parenteral administration can be in the form of aqueous or non- aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions can be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art . [0098] Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents . [0099] The amount of active ingredient that can be combined with the carrier materials to produce a single dosage of the MCH receptor antagonist will vary depending upon the patient and the particular mode of administration. In general, the pharmaceutical compositions may contain an MCH receptor antagonist in the range of about 1 to about 250 mg, more typically, in the range of about 10 to about 200 mg and still more typically, between about 25 to about 150 mg. A daily dose of about 0.01 to about 80 mg/kg body weight, or more typically, between about 0.5 to about 50 mg/kg body weight and even more typically, from about 1 to about 25 mg/kg body weight, may be appropriate. The daily dose can be administered in one to about four doses per day. [0100] The MCH receptor antagonists are administered in such amount as will be therapeutically effective in the treatment or control of the disorder or condition being treated. It will be appreciated that the amount of active ingredients contained in an individual dose of each dosage form need not in itself constitute an effective amount, as the necessary effective amount could be reached by administration of a number of individual doses. Those skilled in the art will appreciate that the quantity of active MCH receptor antagonist to be administered will vary depending upon the age, sex, and body weight of the subject to be treated, the type of disease, or syndrome to be treated, the particular method and scheduling of administration, and what other MCH receptor antagonist, if any, is co-administered. Dosage amounts for an individual patient may thus be above or below the typical dosage ranges. Generally speaking, the MCH receptor antagonist can be employed in any amount known to be effective at treating, preventing or controlling the disorder or condition being treated. The doses may be single doses or multiple doses per day, with the number of doses taken per day and the time allowed between doses varying depending on the individual needs of the patient. Optimization of treatment, including dosage amount, method and time of administration, is thus best determined by a skilled practitioner through close monitoring of patients on an individual basis. Those skilled in the art will appreciate that dosages may also be determined with guidance from Goodman & Goldman, The Pharmacological Basis of Therapeutics, 9th Ed. (1996) , App. II, pp. 1707-1711 and from Goodman & Goldman, The Pharmacological Basis of Therapeutics, 10th Ed. (2001) , App. II, pp. 475-493. Description of the Preferred Embodiments [0101] In one embodiment of the present invention, the MCH receptor antagonist is a compound of Formula I, or a pharmaceutically-acceptable salt, tautomer or prodrug thereof, having the following structure :
Figure imgf000024_0001
[0102] wherein: [0103] W is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano; [0104] X is selected from the group consisting of -OR1, -NR^10, and -SR1; [0105] Y is selected from the group consisting of hydrogen, -N(R7)C(0)NR2R8, -N(R7)C(0)OR2, -N (R7) C (O) R2, -N(R7)S02R2, and -NR2R7; [0106] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(O)-, -CH2N(R9)-, and -N (R12) C (0) N (R9) - ; [0107] R1 is selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl , aryl, aralkyl, heteroaryl, and heteroarylalkyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; [0108] R2 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, arylcycloalkyl, and heteroarylalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; [0109] R3 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano; [0110] R4 is selected from the group consisting of a bond, alkyl, alkenyl, alkynyl,' cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and heteroarylalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, alkoxycarbonyl, and halo; [0111] R5 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyal yl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R5 together with Rs and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0112] Rs is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0113] R7 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano; [0114] R8 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; [0115] R9 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0116] R10 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano; [0117] R11 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano; and [0118] R12 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl , and cyano . [0119] In another embodiment, the MCH receptor antagonist consists of compounds of Formula I, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0120] W is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; [0121] X is selected from the group consisting of -OR1, -NRXR10, and -SR1; [0122] Y is selected from the group consisting of hydrogen, -N(R7)C(0)NR2R8, -N(R7)C(0)OR2, -N (R7) C (O) R2 , -N(R7)S02R2, and -NR2R7; [0123] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(O)-, -C(0)N(R9)-, and -N (R12) C (0) N (R9) - ; [0124] R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl, lower aralkyl, heteroaryl, and lower heteroarylalkyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; [0125] R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, lower arylcycloalkyl, and lower heteroarylalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; [0126] R3 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; [0127] R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower heteroarylalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, lower alkoxycarbonyl, and halo; [0128] Rs is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0129] Rδ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or Rs together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0130] R7 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; [0131] R8 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; [0132] R9 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0133] R10 is selected from the group consisting of - hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; [0134] R11 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; and [0135] R12 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano. [0136] In another embodiment, the MCH receptor antagonist consists of compounds of Formula I, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0137] W is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl, ethoxypropyl , ethoxybutyl, ethoxypentyl , propoxymethyl, propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl, butoxypentyl, pentoxymethyl , pentoxyethyl , pentoxypropyl, pentoxybutyl , pentoxypentyl , phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl , carboxyhexyl , and cyano; [0138] X is selected from the group consisting of -OR1, -NR^-R10, and -SR1; [0139] Y is selected from the group consisting of hydrogen, -N(R7)C(0)NR2R8, -N(R7)C(0)OR2, -N (R7) C (0) R2, -N(R7)S02R2, and -NR2R7; [0140] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(0)~, -C(0)N(R9)-, and -N (R12) C (0) N (R9) - ; [0141] R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl , cyclopropylbutyl , cyclopropylpentyl, cyclobutylmethyl , cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl , cyclobutylpenyyl , cyclopentylmethyl , cyclopentylethyl , cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl , cyclohexylethyl, cyclohexylpropyl , cyclohexylbutyl, cyclohexylpentyl , phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; [0142] R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, f ryl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl , benzyl , diphenylmethyl , triphenylmethyl , phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl , cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl , phenylethenyl, phenylpropenyl , phenylallyl, phenylbutenyl , phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl , phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl , tetrahydroindolyl, dihydroindolyl, indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinσlinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro,- [0143] R3 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl , tetrahydronaphthyl , biphenyl , benzyl , diphenylmethyl , triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl, ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl, butoxypentyl , pentoxymethyl , pentoxyethyl, pentoxypropyl, pentoxybutyl , pentoxypentyl , phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl , carboxyhexyl , and cyano; [0144] R4 is selected from the group consisting of a bond, methyl , ethyl , propyl , butyl , pentyl , hexyl , ethenyl , propenyl , allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl , cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl , phenylallyl, phenylbutenyl , phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl , ethoxycarbonyl , propoxycarbonyl , butoxycarbonyl , pentyloxycarbonyl , hexyloxycarbonyl, chloro, bromo, and fluoro; [0145] R5 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl , phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl , butoxypentyl , pentoxymethyl , pentoxyethyl , pentoxypropyl , pentoxybutyl , pentoxypentyl , phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl , carboxyhexyl , and cyano, or R5 together with R6 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0146] Rs is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl , butoxypentyl, pentoxymethyl , pentoxyethyl , pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl, carboxyhexyl, and cyano, or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0147] R7 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl , tetrahydronaphthyl , biphenyl , benzyl , diphenylmethyl , triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl, carboxyhexyl, and cyano; [0148] R8 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano, or R8 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; [0149] R9 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl, propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl , butoxypentyl , pentoxymethyl , pentoxyethyl , pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl, carboxyhexyl, and cyano, or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0150] R10 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl, carboxyhexyl, and cyano; [0151] R11 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl, carboxyhexyl, and cyano; and [0152] R12 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl , butoxypentyl , pentoxymethyl , pentoxyethyl , pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl , carboxyhexyl , and cyano . [0153] In another embodiment, the MCH receptor antagonist consists of compounds of Formula I, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0154] W is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano; [0155] X is -OR1; [0156] Y is selected from the group consisting of hydrogen, -N(R7)C(0)NRR8, -N(R7)C(0)OR2, -N (R7) C (0) R2, --N (R7) S02R2, and -NR2R7 ; [0157] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(0)-, -C(0)N(R9)-, and -N (R12) C (0) N (R9) - ; [0158] R1 is selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, and heteroarylalkyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; [0159] R2 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, arylcycloalkyl, and heteroarylalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; [0160] R3 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl , and cyano ; [0161] R4 is selected from the group consisting of a bond, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and heteroarylalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, alkoxycarbonyl, and halo; [0162] R5 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0163] R6 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0164] R7 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano; [0165] R8 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; [0166] R9 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0167] R10 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano; [0168] R11 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl , and cyano ; and [0169] R12 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano. [0170] In another embodiment, the MCH receptor antagonist consists of compounds of Formula I, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0171] W is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; [0172] X is -OR1; [0173] Y is selected from the group consisting of hydrogen, -N(R7)C(0)NR2R8, -N(R7)C(0)OR2, -N (R7) C (0) R2, -N(R7)S02R2, and -NR2R7 ; [0174] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(0)-, -C(0)N(R9)-, and -N (R12) C (O) N (R9) - ; [0175] R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl, lower aralkyl, heteroaryl, and lower heteroarylalkyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; [0176] R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, lower arylcycloalkyl, and lower heteroarylalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, .carboxyl, aryloxy, oxo, and halo; [0177] R3 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; [0178] R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower heteroarylalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, lower alkoxycarbonyl, and halo; [0179] R5 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0180] R6 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0181] R7 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyal yl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; [0182] R8 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R8 'together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; [0183] R9 is selected from the group consisting of hydrogen, hydroxy, lower,alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0184] R10 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; [0185] R11 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; and [0186] R12 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano. [0187] In another embodiment, the MCH receptor antagonist consists of compounds of Formula I, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0188] W is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl, carboxyhexyl, and cyano; [0189] X is -OR1; [0190] Y is selected from the group consisting of hydrogen, -N(R7)C(0)NR2R8, -N(R7)C(0)OR2, -N (R7) C (O) R2 , -N(R7)S02R2, and -NR2R7 ; [0191] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(O)-, -C(0)N(R9)-, and -N (R12) C (0) N (R9) - ; [0192] R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl , cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; [0193] R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl , cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl , phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthyleye1ohexyl , or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl , tetrahydroindolyl, dihydroindolyl , indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; [0194] R3 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl , carboxyhexyl , and cyano; [0195] R4 is selected from the group consisting of a bond, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, acetylenyl, propynyl , butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl , cyclohexylpentyl , phenylethenyl, phenylpropenyl , phenylallyl, phenylbutenyl , phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl , ethoxycarbonyl , propoxycarbonyl , butoxycarbonyl , pentyloxycarbonyl , hexyloxycarbonyl , chloro, bromo, and fluoro; [0196] R5 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl , tetrahydronaphthyl , biphenyl , benzyl , diphenylmethyl , triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano, or R5 together with Rs and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0197] R6 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl , tetrahydronaphthyl , biphenyl , benzyl , diphenylmethyl , triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl, carboxyhexyl, and cyano, or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0198] R7 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl , butoxypentyl , pentoxymethyl , pentoxyethyl , pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl, carboxyhexyl, and cyano; [0199] R8 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl, propoxypropyl , propoxybutyl , propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl, carboxyhexyl, and cyano, or R8 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; [0200] R9 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl, butoxybutyl , butoxypentyl , pentoxymethyl , pentoxyethyl , pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl, carboxyhexyl, and cyano, or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0201] R10 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl , butoxypentyl , pentoxymethyl , pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano; [0202] R11 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl , carboxyhexyl , and cyano; and [0203] R12 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl , carboxyhexyl , and cyano . [0204] In another embodiment, the MCH receptor antagonist is selected from a subclass of compounds of Formula I represented by Formula II:
Figure imgf000049_0001
[0205] wherein: [0206] W is selected from the group consisting of hydrogen, hydroxy, alkyl, and alkoxy; [0207] X is selected from the group consisting of -OR1, -NR3^10, and -SR1; [0208] Y is selected from the group consisting of hydrogen, -N(R7)C(0)NR2R8, -N(R7)C(0)OR2, -N (R7) C (O) R2, -N(R7)S02R2, and -NRR7 ; [0209] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(O)-, -C(0)N(R9)-, and -N (R12) C (0) N (R9) - ; [0210] R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; [0211] R2 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; [0212] R4 is selected from the group consisting of a bond, alkyl, alkenyl, and cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, and halo; [0213] R5 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0214] R6 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or Rδ together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0215] R7 is selected from the group consisting of hydrogen, alkyl, and aryl; [0216] R8 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; [0217] R9 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0218] R10 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl; and [0219] R12 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl , and carboxyalkyl ; [0220] or a pharmaceutically-acceptable salt, tautomer or prodrug thereof . [0221] In another embodiment, the MCH receptor antagonist consists of compounds of Formula II, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0222] W is selected from the group consisting of hydrogen, hydroxy, lower alkyl, and lower alkoxy; [0223] X is selected from the group consisting of -OR1, -NR^10, and -SR1; [0224] Y is selected from the group consisting of hydrogen, -N(R7)C(0)NR2R8, -N(R7)C(0)OR2, -N (R7) C (0) R2, -N(R7)S02R2, and -NR2R7; [0225] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(O)-, -C(0)N(R9)-, and -N (R12) C (O) N (R9) - ; [0226] R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; [0227] R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; [0228] R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo; [0229] R5 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R5 together with Rδ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0230] R6 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0231] R7 is selected from the group consisting of hydrogen, lower alkyl, and aryl; [0232] R8 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; [0233] R9 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0234] R10 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl; and [0235] R12 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl. [0236] In another embodiment, the MCH receptor antagonist consists of compounds of Formula II, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0237] W is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, and hexyloxy; [0238] X is selected from the group consisting of -OR1, -NR^10, and -SR1; [0239] Y is selected from the group consisting of hydrogen, -N(R7)C(0)NR2R8, -N(R7)C(0)OR2, -N (R7) C (0) R2, -N(R7)S02R2, and -NR2R7 ; [0240] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(O)-, -C(0)N(R9)-, and -N (R12) C (O) N (R9) - ; [0241] R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; [0242] R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl , furyl , thienyl , pyrrolyl , pyrazolyl , imidazolyl , triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl , benzyl , diphenylmethyl , triphenylmethyl , phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl , cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl , phenylpropenyl , phenylallyl, phenylbutenyl , phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl , biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl , tetrahydroindolyl, dihydroindolyl , indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; [0243] R3 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl , butoxypentyl , pentoxymethyl , pentoxyethyl , pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl, carboxyhexyl, and cyano; [0244] R4 is selected from the group consisting of a bond, methyl , ethyl , propyl , butyl , pentyl , hexyl , ethenyl , propenyl , allyl, butenyl, pentenyl, acetylenyl, propynyl , butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl , cyclohexylmethyl , cyclohexylethyl, cyclohexylpropyl , cyclohexylbutyl , cyclohexylpentyl, phenylethenyl, phenylpropenyl , phenylallyl, phenylbutenyl , phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl , ethoxycarbonyl , propoxycarbonyl , butoxycarbonyl , pentyloxycarbonyl, hexyloxycarbonyl , chloro, bromo, and fluoro; [0245] R5 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl , tetrahydronaphthyl , biphenyl , benzyl , diphenylmethyl , triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , butoxybutyl , butoxypentyl , pentoxymethyl , pentoxyethyl , pentoxypropyl , pentoxybutyl , and pentoxypentyl , or R5 together with R6 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0246] R6 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , butoxybutyl , butoxypentyl , pentoxymethyl , pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R6 together with R5 and the nitrogen to which they are' attached may form a pyrrolidinyl or a piperidinyl ring; [0247] R7 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, and biphenyl; [0248] R8 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl , butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl , pentoxypentyl , carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl , or R8 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; [0249] R9 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0250] R10 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl ; and [0251] R12 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethy1 , methoxyethy1 , methoxypropy1 , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl , pentoxymethyl , pentoxyethyl , pentoxypropyl , pentoxybutyl , pentoxypentyl , carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl . [0252] In another embodiment, the MCH receptor antagonist is selected from a subclass of compounds of Formula I represented by Formula III:
Figure imgf000059_0001
[0253] wherein: [0254] X is selected from the group consisting of -OR1 and -SR1; [0255] Y is selected from the group consisting of hydrogen, -N(R7)C(0)NR2R8, -N(R7)C(0)OR2, -N (R7) C (0) R2, -N(R7)S02R2, and -NR2R7 ; [0256] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(0)N(R9)-, and -NHC(0)NR9-; [0257] R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; [0258] R2 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; [0259] R4 is selected from the group consisting of a bond, alkyl, alkenyl, and cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, and halo; [0260] R5 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or RΞ together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0261] R6 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0262] R7 is selected from the group consisting of hydrogen, alkyl, and aryl; [0263] R8 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; [0264] R9 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0265] R10 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl; and [0266] R12 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl; [0267] or a pharmaceutically-acceptable salt, tautomer or prodrug thereof . [0268] In another embodiment, the MCH receptor antagonist consists of compounds of Formula III, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0269] X is selected from the group consisting of -OR1 and -SR1; [0270] Y is selected from the group consisting of hydrogen, -N(R7)C(0)NR2R8, -N(R7)C(0)OR2, -N (R7) C (0) R2, -N(R7)S02R2, and -NR2R7 ; [0271] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(0)N(R9)-, and -NHC (0) NR9- ; [0272] R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; [0273] R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; [0274] R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo; [0275] R5 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0276] Rε is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0277] R7 is selected from the group consisting of hydrogen, lower alkyl, and aryl; [0278] R8 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; [0279] R9 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0280] R10 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl; and [0281] R12 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl , lower alkoxyalkyl , and lower carboxyalkyl . [0282] In another embodiment, the MCH receptor antagonist consists of compounds of Formula III, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0283] X is selected from the group consisting of -OR1 and -SR1; [0284] Y is selected from the group consisting of hydrogen, -N(R7)C(0)NR2R8, -N(R7)C(0)OR2, -N (R7) C (O) R2, -N(R7)S02R2, and -NR2R7; [0285] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(0)N(R9)-, and -NHC(0)NR9-; [0286] R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; [0287] R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl , benzyl , diphenylmethyl , triphenylmethyl , phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl , cyclohexylpropyl , cyclohexylbutyl, cyclohexylpentyl , phenylethenyl , phenylpropenyl, phenylallyl, phenylbutenyl , phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl , biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl , tetrahydroindolyl, dihydroindolyl , indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; [0288] R3 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl, carboxyhexyl, and cyano; [0289] R4 is selected from the group consisting of a bond, methyl , ethyl , propyl , butyl , pentyl , hexyl , ethenyl , propenyl , allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl , hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl , cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl , phenylallyl, phenylbutenyl, phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl , ethoxycarbonyl , propoxycarbonyl , butoxycarbonyl , pentyloxycarbonyl, hexyloxycarbonyl , chloro, bromo, and fluoro; [0290] R5 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl, methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl , pentoxypropyl , pentoxybutyl , and pentoxypentyl , wherein R5 together with R6 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0291] R6 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , butoxybutyl , butoxypentyl , pentoxymethyl , pentoxyethyl , pentoxypropyl , pentoxybutyl , and pentoxypentyl , or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0292] R7 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, and biphenyl; [0293] R8 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl , tetrahydronaphthyl , biphenyl , benzyl , diphenylmethyl , triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl , butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl , or R8 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; [0294] R9 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl , tetrahydronaphthyl , biphenyl , benzyl , diphenylmethyl , triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl , butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl , pentoxypentyl , carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl , or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0295] R10 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl ; and [0296] R12 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl , tetrahydronaphthyl , biphenyl , benzyl , diphenylmethyl , triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl , butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl , pentoxypentyl , carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl . [0297] In another embodiment, the MCH receptor antagonist is selected from a subclass of compounds of Formula I represented by Formula IV:
Figure imgf000068_0001
[0298] wherein: [0299] X is selected from the group consisting of -OR1 and -SR1; [0300] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(0)N(R9)-, and -NHC (O)NR9- ; [0301] R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; [0302] R2 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; [0303] R4 is selected from the group consisting of a bond, alkyl, alkenyl, and cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, and halo; [0304] RΞ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R5 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0305] R6 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0306] R7 is selected from the group consisting of hydrogen, alkyl, and aryl; [0307] R8 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; [0308] R9 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0309] R10 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl; and [0310] R12 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, a1koxya1ky1 , and carboxya1ky1 ; [0311] ' or a pharmaceutically-acceptable salt, tautomer or prodrug thereof . [0312] In another embodiment, the MCH receptor antagonist consists of compounds of Formula IV, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0313] X is selected from the group consisting of -OR1 and -SR1; [0314] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(0)N(R9)-, and -NHC(0)NR9-; [0315] R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; [0316] R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; [0317] R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo; [0318] R5 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0319] R6 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0320] R7 is selected from the group consisting of hydrogen, lower alkyl, and aryl; [0321] R8 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; [0322] R9 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0323] R10 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl , lower alkoxyalkyl , and lower carboxyalkyl ; and [0324] R12 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl. [0325] In another embodiment, the MCH receptor antagonist consists of compounds of Formula IV, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0326] X is selected from the group consisting of -OR1 and -SR1; [0327] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(0)N(R9)-, and -NHC (O) NR9- ; [0328] R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; [0329] R2 is selected from the group consisting of methyl, ethyl , propyl , butyl , pentyl , hexyl , cyclopropyl , cyclobutyl , cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl , cyclohexylpentyl, phenylethenyl, phenylpropenyl , phenylallyl, phenylbutenyl, phenylpentenyl , phenyleye1opropyl , phenyleye1obutyl , phenylcyclopentyl, phenyleye1ohexyl , biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl , tetrahydroindolyl, dihydroindolyl , indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R2 or ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; [0330] R3 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl , hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl , carboxyhexyl , and cyano ; [0331] R4 is selected from the group consisting of a bond, methyl , ethyl , propyl , butyl , pentyl , hexyl , ethenyl , propenyl , allyl, butenyl, pentenyl, acetylenyl, propynyl , butynyl, pentynyl , hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl , phenylallyl, phenylbutenyl, phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl , ethoxycarbonyl , propoxycarbonyl , butoxycarbonyl , pentyloxycarbonyl, hexyloxycarbonyl , chloro, bromo, and fluoro ,- [0332] R5 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , butoxybutyl, butoxypentyl , pentoxymethyl , pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R5 together with Rs and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0333] R6 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , butoxybutyl , butoxypentyl , pentoxymethyl , pentoxyethyl , pentoxypropyl , pentoxybutyl , and pentoxypentyl , or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0334] R7 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, and biphenyl; [0335] R8 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl , or R8 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; [0336] R9 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl , butoxypentyl , pentoxymethyl , pentoxyethyl , pentoxypropyl , pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl , or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0337] R10 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl , pentoxypentyl , carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl ; and [0338] R12 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl, butoxypentyl , pentoxymethyl , pentoxyethyl , pentoxypropyl , pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl . [0339] In another embodiment, the MCH receptor antagonist is selected from a subclass of compounds of Formula I represented by Formula V:
Figure imgf000077_0001
[0340] wherein: [0341] X is selected from the group consisting of -OR1 and -SR1; [0342] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(0)N(R9)-, and -NHC(0)NR9-; [0343] R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; [0344] R2 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; [0345] R4 is selected from the group consisting of a bond, alkyl, alkenyl, and cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, and halo; [0346] R5 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0347] Rs is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0348] R7 is selected from the group consisting of hydrogen, alkyl, and aryl; [0349] R8 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; and [0350] R9 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0351] or a pharmaceutically-acceptable salt, tautomer or prodrug thereof . [0352] In another embodiment, the MCH receptor antagonist consists of compounds of Formula V, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0353] X is selected from the group consisting of -OR1 and -SR1; [0354] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(0)N(R9)-, and -NHC(0)NR9-; [0355] R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; [0356] R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; [0357] R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo; [0358] R5 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl , or RΞ together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0359] Rs is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl , or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0360] R7 is selected from the group consisting of hydrogen, lower alkyl, and aryl; [0361] R8 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; and [0362] R9 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring. [0363] In another embodiment, the MCH receptor antagonist consists of compounds of Formula V, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0364] X is selected from the group consisting of -OR1 and
[0365] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(0)N(R9)-, and -NHC(0)NR9-; [0366] R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; [0367] R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl , cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl , cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl , phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl , tetrahydroindolyl, dihydroindolyl , indolinyl, octahydroquinolinyl , hexahydroquinolinyl , tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; [0368] R4 is selected from the group consisting of a bond, methyl , ethyl , propyl , butyl , pentyl , hexyl , ethenyl , propenyl , allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl , cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl , phenylallyl, phenylbutenyl, phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl , ethoxycarbonyl , propoxycarbonyl , butoxycarbonyl , pentyloxycarbonyl, hexyloxycarbonyl, chloro, bromo, and fluoro; [0369] R5 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl , pentoxypropyl , pentoxybutyl , and pentoxypentyl , or R5 together with R6 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0370] R6 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl , butoxybutyl , butoxypentyl , pentoxymethyl , pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0371] R7 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, and biphenyl ,- [0372] R8 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl, methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl , pentoxypentyl , carboxymethyl , carboxyethyl , carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R8 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; and [0373] R9 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring. [0374] In another embodiment, the MCH receptor antagonist is selected from a subclass of compounds of Formula I represented by Formula VI :
Figure imgf000084_0001
[0375] wherein: [0376] X is selected from the group consisting of -OR1 and -SR1; [0377] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(0)N(R9)-, and -NHC(0)NR9-; [0378] R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; [0379] R2 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; [0380] R4 is selected from the group consisting of a bond, alkyl, alkenyl, and cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, and halo; [0381] Rs is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0382] R6 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or Rs together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0383] R7 is selected from the group consisting of hydrogen, alkyl, and aryl; and [0384] R9 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0385] or a pharmaceutically-acceptable salt, tautomer or prodrug thereof . [0386] In another embodiment, the MCH receptor antagonist consists of compounds of Formula VI, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0387] X is selected from the group consisting of -OR1 and -SR1; [0388] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(0)N(R9)-, and -NHC(0)NR9-; [0389] R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; [0390] R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; [0391] R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo; [0392] R5 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0393] R6 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or Rs together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0394] R7 is selected from the group consisting of hydrogen, lower alkyl, and aryl; [0395] R8 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; and [0396] R9 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring. [0397] In another embodiment, the MCH receptor antagonist consists of compounds of Formula VI, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0398] X is selected from the group consisting of -OR1 and -SR1; [0399] Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(0)N(R9)-, and -NHC(0)NR9-; [0400] R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; [0401] R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl , cyclohexylethyl, cyclohexylpropyl , cyclohexylbutyl , cyclohexylpentyl, phenylethenyl, phenylpropenyl , phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl , tetrahydroindolyl, dihydroindolyl , indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; [0402] R4 is selected from the group consisting of a bond, methyl , ethyl , propyl , butyl , pentyl , hexyl , ethenyl , propenyl , allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl , phenylallyl, phenylbutenyl , phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl , ethoxycarbonyl , propoxycarbonyl , butoxycarbonyl , pentyloxycarbonyl, hexyloxycarbonyl, chloro, bromo, and fluoro; [0403] R5 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl, ethoxyethyl, ethoxypropy1 , ethoxybut 1 , ethoxypentyl , butoxybutyl , butoxypentyl , pentoxymethyl , pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R5 together with R6 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0404] R6 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0405] R7 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, and biphenyl; [0406] R8 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl , butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R8 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; and [0407] R9 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl , tetrahydronaphthyl , biphenyl , benzyl , diphenylmethyl , triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl , butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl , or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring. [0408] In another embodiment, the MCH receptor antagonist is selected from a subclass of compounds of Formula I represented by Formula VII:
Figure imgf000091_0001
[0409] wherein: [0410] R1 is selected from the group consisting of cycloalkyl and aryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, and halo; [0411] R2 is selected from the group consisting of alkyl, aryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, aryloxy, and halo; [0412] Rs is selected from the group consisting of hydrogen and alkyl, or R5 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0413] R6 is selected from the group consisting of hydrogen and alkyl , or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; and [0414] R8 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, and aryl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; [0415] or a pharmaceutically-acceptable salt, tautomer or prodrug thereof . [0416] In another embodiment, the MCH receptor antagonist consists of compounds of Formula VII, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0417] R1 is selected from the group consisting of lower cycloalkyl and aryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, and halo; [0418] R2 is selected from the group consisting of lower alkyl, aryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, aryloxy, and halo; [0419] R5 is selected from the group consisting of hydrogen and lower alkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; [0420] R6 is selected from the group consisting of hydrogen and lower alkyl, or Rs together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; and [0421] R8 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, and aryl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system. [0422] In another embodiment, the MCH receptor antagonist consists of compounds of Formula VII, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0423] R1 is selected from the group consisting of cyclopentyl, cyclohexyl, phenyl, naphthyl, and biphenyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, hydroxy, methoxy, ethoxy, propoxy, chloro, bromo, and fluoro; [0424] R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, phenylethyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, phenylethenyl , phenylpropenyl , phenylcyclopropyl, biphenylcyclopropyl, and naphthylcyclopropyl , or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of dihydroisoindolyl, dihydroindolyl , tetrahydroisoquinolinyl, and tetrahydroquinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, hydroxy, methoxy, ethoxy, propoxy, phenoxy, naphthyloxy, biphenylyloxy, chloro, bromo, and fluoro; [0425] R5 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, and hexyl, or R5 together with Rs and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; [0426] R6 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, and hexyl, or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; and [0427] R8 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, and biphenyl, or R8 together with R2 and the nitrogen to which they are attached may form a ring selected from the group consisting of dihydroisoindolyl , dihydroindolyl , tetrahydroisoquinolinyl, and tetrahydroquinolinyl . [0428] In another embodiment, the MCH receptor antagonist consists of compounds of Formula VII, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein: [0429] R1 is selected from the group consisting of phenyl, and naphthyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, chloro, and fluoro; [0430] R2 is selected from the group consisting of methyl, ethyl, phenyl, naphthyl, biphenyl, benzyl, phenylethyl, cyclopentylethyl, phenylethenyl, phenylcyclopropyl, or R2 together with R8 and the nitrogen to which they are attached may form a dihydroisoindolyl ring, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, propyl, methoxy, phenoxy, chloro, bromo, and fluoro; [0431] R5 is hydrogen or R5 together with R6 and the nitrogen to which they are attached form a pyrrolidinyl ring; [0432] Rδ is hydrogen or R6 together with R5 and the nitrogen to which they are attached form a pyrrolidinyl ring; and [0433] R8 is selected from the group consisting of hydrogen, methyl, and phenyl, or R8 together with R2 and the nitrogen to which they are attached may form a dihydroisoindolyl ring. [0434] In another embodiment, the compound of Formula I is selected from the group of compounds listed in Table 1. TABLE 1
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0002
[0435] In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure :
Figure imgf000109_0001
[0436] wherein R2a, R2b, R2c, R , and R2e are as defined in Table 2 .
Table 2
Figure imgf000109_0003
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
Figure imgf000127_0001
Figure imgf000128_0001
Figure imgf000129_0001
Figure imgf000130_0001
Figure imgf000131_0001
Figure imgf000132_0001
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
Figure imgf000137_0001
Figure imgf000138_0001
Figure imgf000139_0001
Figure imgf000140_0001
Figure imgf000141_0001
Figure imgf000142_0001
Figure imgf000143_0001
Figure imgf000144_0001
Figure imgf000146_0001
Figure imgf000147_0001
Figure imgf000148_0001
Figure imgf000149_0001
Figure imgf000150_0001
Figure imgf000151_0001
Figure imgf000152_0001
Figure imgf000153_0001
Figure imgf000154_0001
Figure imgf000155_0001
Figure imgf000156_0001
Figure imgf000157_0001
Figure imgf000158_0001
Figure imgf000159_0001
Figure imgf000160_0001
Figure imgf000161_0001
Figure imgf000162_0001
Figure imgf000163_0001
Figure imgf000164_0001
Figure imgf000165_0001
Figure imgf000166_0001
Figure imgf000167_0001
Figure imgf000168_0001
Figure imgf000169_0001
Figure imgf000170_0001
Figure imgf000171_0001
Figure imgf000172_0001
Figure imgf000173_0001
Figure imgf000174_0001
Figure imgf000175_0001
Figure imgf000176_0001
Figure imgf000177_0001
Figure imgf000178_0001
Figure imgf000179_0001
Figure imgf000180_0001
Figure imgf000181_0001
Figure imgf000182_0001
Figure imgf000183_0001
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001
Figure imgf000191_0001
Figure imgf000192_0001
Figure imgf000193_0001
Figure imgf000194_0001
Figure imgf000195_0001
Figure imgf000197_0001
Figure imgf000198_0001
Figure imgf000199_0001
Figure imgf000200_0001
Figure imgf000201_0001
Figure imgf000202_0001
Figure imgf000203_0001
Figure imgf000204_0001
Figure imgf000205_0001
Figure imgf000206_0001
Figure imgf000207_0001
Figure imgf000208_0001
Figure imgf000209_0001
Figure imgf000210_0001
Figure imgf000211_0001
Figure imgf000212_0001
Figure imgf000213_0001
Figure imgf000214_0001
Figure imgf000215_0001
Figure imgf000216_0001
Figure imgf000217_0001
Figure imgf000218_0001
Figure imgf000219_0001
Figure imgf000220_0001
Figure imgf000221_0001
Figure imgf000222_0001
Figure imgf000223_0001
Figure imgf000224_0001
Figure imgf000225_0001
Figure imgf000226_0001
Figure imgf000227_0001
Figure imgf000228_0001
Figure imgf000229_0003
[0437] In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure :
Figure imgf000229_0001
[0438] wherein R2a, R2b, R2c, R2d, and R2e are as defined in Table 2. [0439] In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure :
Figure imgf000229_0002
[0440] wherein R2a, R2b, R2c, R2 , and R2e are as defined in Table 2. [0441] In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure:
Figure imgf000230_0001
[0442] wherein R2a, Rb, R2c, R2d, and R2e are as defined in Table 2. [0443] In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure :
Figure imgf000230_0002
[0444] wherein R2a, R2b, R2c, R2d, and R2e are as defined in Table 2. [0445] In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure :
Figure imgf000230_0003
[0446] wherein R2a, R2b, R2c, R2d, and R2e are as defined in Table 2 . [0447] In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure :
Figure imgf000231_0001
[0448] wherein R2a, R , R2c, R2d, and R2e are as defined in Table 2. [0449] In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure :
Figure imgf000231_0002
[0450] wherein R2a, R2b, R2c, R2d, and R2e are as defined in Table 2. [0451] In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure :
Figure imgf000231_0003
[0452] wherein R , R2b, R2c, R2d, and R2e are as defined in Table 2. [0453] In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure :
Figure imgf000232_0001
[0454] wherein R2a, R2b, R2c, Rd, and R2e are as defined in Table 2. [0455] In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure :
Figure imgf000232_0002
[0456] wherein R2 , R2b, R2c, R , and R2e are as defined in Table 2. [0457] In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure :
Figure imgf000233_0001
[0458] wherein R2a, Rb, R2c, R2d, and R2e are as defined in Table 2. [0459] In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure :
Figure imgf000233_0002
[0460] wherein R2a, R2b, R2c, R2d, and R2e are as defined in Table 2. [0461] In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure :
Figure imgf000233_0003
[0462] wherein R ,2zaa , ,?2bΏ , ,2ΛcC , R ,2Ada , and R2e are as defined in Table 2 . [0463] In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure :
Figure imgf000234_0001
[0464] wherein R , R2 , R , R , and R2e are as defined in Table 2. [0465] In another embodiment, the compound of Formula I is selected from the group of compounds of Formula V having the structure :
Figure imgf000234_0002
[0466] wherein R2a, R2b, R2c, R2d, and R2e are as defined in Table 2. [0467] The compounds of Formula I are MCH receptor antagonists, as demonstrated by the ligand binding assays described hereinbelow. MCH receptor antagonist activity has been correlated with pharmaceutical activity for the treatment of eating disorders such as obesity and hyperphagia, and diabetes. Compounds of Formula I exhibit good activity in standard in vitro MCH calcium mobilization assays and/or receptor binding assays, specifically in the assays described hereinbelow, see Examples 23 and 24. Generally, compounds of Formula I have an Kj. of about 10 μM or less, preferably about 1 μM or less, more preferably about 100 nM or less, or even more preferably about 10 nM or less, as determined by a standard in vi tro MCH receptor mediated calcium mobilization assay as exemplified by Example 23, hereinbelow. Generally compounds of Formula I are MCH receptor antagonists and exhibit IC50 values of about 10 μM or less, preferably about 1 μM or less, more preferably about 100 nM or less, or even more preferably about 10 nM or less, as determined by a standard in vi tro MCH receptor binding assay such as is described hereinbelow in Example 24. [0468] Preferably, the MCH receptor antagonists of Formula I bind specifically, and still more preferably with high affinity, to MCH receptors. [0469] The following examples illustrate the invention.
Example 1
Figure imgf000236_0001
OH R2 Step #3 DBU, DMF overnight, r.t.
Figure imgf000236_0002
Step 1
Figure imgf000236_0003
[0470] To a 2 L glass bottle was added 4-formyl-3- methoxyphenoxy-polystyrene resin (100-180 mesh, 1.1 mmol/g loading, 20 g, 22 mmol) , amine (5 eq, 110 mmol) , and anhydrous DCE (500 mL) . The resulting mixture was shaken for one hour at room temperature. Then, Na(OAc)3BH (5 eq, 110 mmol) was added and the mixture was shaken overnight at room temperature. The mixture was degassed every half-hour for the first three hours. The resin was filtered and washed with MeOH (2x) and DCM (2x) to afford 1. Step 2
Figure imgf000237_0001
[0471] To a 2 L glass bottle was added 1, 4-fluoro-3- nitrobenzoic acid (24.4 mmol, 132 mmol) , HOBt (18 g, 132 mmol) , DIC (42 mL, 264 mmol) , and DMF (500 mL) . The resulting mixture was shaken overnight at room temperature. The resin was filtered and washed with DMF (2x) , MeOH (2x) , and DCM (2x) to afford 2.
Step 3
Figure imgf000237_0002
[0472] To a 2 L glass bottle was added 2, phenol (27 g, 220 mmol) , DBU (20 mL, 132 mmol) , and DMF (400 mL) . The resulting mixture was shaken overnight at room temperature. Then, the resin was filtered and washed with DMF (2x) and DCM (2x) to afford 3. Step 4
Figure imgf000238_0001
[0473] To a 2 L glass bottle was added 3, Tin (II) Cl • 2H20 (49.5 g, 220 mmol) and DMF (400 mL) . The resulting mixture was then shaken overnight at room temperature. The resin was filtered and washed with DMF (2x) and DCM (2x) to afford 4.
Example 2
Figure imgf000238_0002
Method 1 [0474] Starting material (10 mg, 0.021 mmol) was combined with 1,2-dibromoethane (2.3 μL, 0.025 mmol) and NaH (1 mg, 0.042 mmol) in 0.5 mL DMF at room temperature. The mixture was then heated to 80 °C for 1 hour. The reaction mixture was worked up with water and EtOAc . Method 2 [0475] Starting material (20 mg, 0.04 mmol) was combined with 1,2-diiodoethane (14.3 mg, 0.05 mmol) and NaH (2 mg, 0.08 mmol) in 0.5 mL DMF, then reacted as described above.
Example 3
Figure imgf000239_0001
[0476] To a peptide vessel was added resin (1.1 mmol/g loading, 100 mg, 0.11 mmol), 2 -methoxyphenylisocyanate (1.1 mmol) , and pyridine: DCM (5 mL, 1:1 ratio) . The resulting mixture was shaken overnight at room temperature . The resin was washed with DCM (2x) . Then, 30% TFA in DCM (10 mL) was added and the resulting mixture was shaken for 45 min. at room temperature. The resin was filtered and washed with DCM (2x) . The filtrate was concentrated to afford 30. [0477] Examples 4-16 were prepared according to the procedure shown in Example 3. Example 4
Figure imgf000240_0001
Example 5
Figure imgf000240_0002
Example 6
Figure imgf000241_0001
Example 7
Figure imgf000241_0002
Example 8
Figure imgf000242_0001
Example 9
Figure imgf000242_0002
36 Example 10
Figure imgf000243_0001
Example 11
Figure imgf000243_0002
Example 12
Figure imgf000244_0001
Example 13
Figure imgf000244_0002
Example 14
Figure imgf000245_0001
Example 15
Figure imgf000245_0002
Example 16
Figure imgf000246_0001
Example 17
Figure imgf000246_0002
[0478] To a round bottom flask was added resin (500 mg, 0.55 mmol) and DCM (15 mL) . The resulting mixture was cooled to -78°C. Then, 20% phosgene in toluene (540 mg) was added dropwise. The resulting mixture was warmed to room temperature and shaken for 3 hours . The resin was filtered and washed with DCM (2x) . The resin was transferred to a peptide vessel and excess (10-15 eq) of aminopyridine along with 15 mL of DCM were added. The resulting mixture was shaken overnight at room temperature. The resin was washed with DCM (2x) . Then, 30% TFA in DCM (50 mL) was added and the resulting mixture was shaken for 45 min. at room temperature. The resin was filtered and washed with DCM (2x) . The filtrate was concentrated to afford 44.
Example 18
Figure imgf000247_0001
[0479] To a peptide vessel was added resin (1.1 mmol/g, 200 mg, 0.22 mmol), phenylchloroformate (143 μL, 1.1 mmol), and DCM:pyridine (7 mL, 1:1 ratio) . The resulting mixture was shaken overnight at room temperature. The resin was washed with DCM (2x) . Then, 30% TFA in DCM (50 mL) was added and the resulting mixture was shaken for 45 min. at room temperature. The resin was filtered and washed with DCM (2x) . The filtrate was concentrated to afford 45.
Example 19
Figure imgf000248_0001
[0480] To a peptide vessel was added resin (1.1 mmol/g, 1.1 g, 1.21 mmol), 1, 1-dimethylethyl 2-oxoethyl (phenyl) carbamate (490 mg, 3.63 mmol), and DCM:DMF (10 mL, 1:1 ratio). The mixture was shaken for 30 min. at room temperature. Then, Na(OAc)3BH (1.27 g, 6.05 mmol) was added and the mixture was shaken overnight at room temperature. The mixture was degassed every half hour for the first 3 hours. The resin was washed with MeOH (2x) and DCM (2x) . Then, 30%TFA in DCM (50 mL) was added and resulting mixture was shaken for 45 min. at room temperature. The resin was filtered and washed with DCM (2x) . The filtrate was concentrated and dried. Then, phosgene (27.1 μL, 0.274 mmol) and DCM:pyridine (5 mL, 1:1 ratio) were added to the crude mixture. The resulting mixture was stirred at room temperature for 45 min. The mixture was concentrated and purified by column chromatography to afford 62. Example 20
Figure imgf000249_0001
[0481] To a peptide vessel was added resin (1.1 mmol/g, 500 mg, 0.55 mmol), acetaldehyde (93 μL, 1.65 mmol), and DCM:DMF (8 mL, 1:1 ratio) . The mixture was shaken for 30 min. at room temperature. Then, Na(OAc)3BH (580 mg, 2.75 mmol) was added and the mixture was shaken overnight at room temperature . The mixture was degassed every half hour for the first three hours. The resin was washed with MeOH (2x) and DCM (2x) . Then, isocyanatobenzene (327 μL, 2.75 mmol) and DCM (10 mL) were added to the resin in the peptide vessel . The resulting mixture was shaken overnight at room temperature . The resin was washed with DCM (2x) . Then, 30% TFA in DCM (50 mL) was added and resulting mixture was shaken for 45 min. at room temperature. The resin was filtered and washed with DCM (2x) . The filtrate was concentrated to afford 49.
Example 21
Figure imgf000250_0001
[0482] To a round bottom flask was added resin (1.1 mmol/g, 400 mg, 0.44 mmol) and DCM (7 mL) . The resulting mixture was stirred at -78°C and phosgene (217 mg, 2.2 mmol) was added dropwise. The mixture was warmed up to room temperature and shaken for 3 hours. The resin was washed with DCM (2x) and transferred to a peptide vessel. Then, 1,2,3,4- tetrahydroquinoline (585 μL, 4.4 mmol) was added to the vessel. The resulting mixture was shaken for 2 hours. The resin was washed with DCM (2x) . Then, 30% TFA in DCM (30 mL) was added and resulting mixture was shaken' for 45 min. at room temperature. The resin was filtered and washed with DCM (2x) . The filtrate was concentrated to afford 46.
Example 22
Figure imgf000251_0001
63
[0483] To a 20 ml vial was added 1- ( (4-fluoro-3- nitrophenyl) carbonyl) -2- (1-pyrrolidinylmethyl) yrrolidine (520 mg, 1.62 mmol), 3 , 4-dimethylphenol (237 mg, 1.94 mmol), DBU (271 μL, 1.78 mmol) , and DMF (10 mL) . The resulting mixture was stirred overnight at room temperature . The mixture was extracted with H20 and EtOAc. The organic layers were combined, dried with MgS04, and concentrated to give a crude intermediate. The intermediate was purified by column chromatography to give a pure intermediate. Then, EtOH:H20 (3:1) and Na2S204 (10 eq) were, added to the intermediate. The resulting mixture was refluxed overnight. Then, the mixture was cooled to room temperature and extracted with H20 and EtOAc. The organic layers were combined, dried with MgS0 , and concentrated to give a crude intermediate. The crude intermediate was purified by column chromatography to give a pure intermediate. The purified intermediate was placed in a round bottom flask and DCM and phenylisocyanate (1 eq) were added. The resulting mixture was stirred at room temperature for 1 hour. The solvent was removed and the crude desired product was purified by column chromatography to afford 63.
Example 23 Functional Assay
[0484] Human embryonic kidney cells (293 total) expressing either human, rat, or mouse MCH receptor were harvested from 150 mm culture dishes using PBS. Spinning at 1500 rpm for 2 minutes initially pelleted cells. The resulting pellet was then homogenized in 15 mL ice cold sucrose buffer (25 mM HEPES, 0.3 M sucrose, pH 7.4) with a motorized, glass fitted, Teflon® homogenizer. The homogenate was centrifuged at 48,000 X g at 4°C for 10 minutes, resuspended in 15 mL assay buffer (25 mM HEPES, 10 mM MgCl2, 0.2% BSA, 0.1 mg/mL STI, 0.1 mg/mL Pefabloc®, 1 μM Phosphoramidon, pH 7.4) with a Tissue-Tearor® (Biospec Products) and centrifuged again at 48,000 X g for 10 minutes. The pellet was homogenized for a third time in 15 mL assay buffer using the Tissue-Tearor® and again centrifuged at 48,000 X g for 10 minutes. The resulting pellet was resuspended in assay buffer at a wet weight concentration of 10-20 mg/mL. [0485] Pharmacological analyses were conducted using either a HT-PS100 device (Axiom Biotechnologies, San Diego, CA) , which provides high-resolution dose-response fluorometric measurements of [Ca++] i mobilization, or using a FLIPR® device (Molecular Devices, Sunnyvale, CA) .
HT-PS100 Protocol: [0486] Materials: HEK 293 cells were stably transfected with the rat MCH 1 receptor and maintained under G418 antibiotic pressure. HT-PS100 assay buffer consisted of Physiological Saline Solution (145 mM NaCl, 5.4 mM KCL, 1.0 mM NaH2P04, 1.8 mM CaCl2, 0.8 mM MgS04, 15.0 mM HEPES, pH 7.4, 11.2 mM glucose) + 50 μM Pluronic-F127. MCH peptide (Amgen, Inc.) was reconstituted in assay buffer and served as the positive agonist control for all experiments. Test compounds were prepared as 10 mM stocks in 100% DMSO and diluted to a top end working concentration of 100 μM in 96 well plates. [0487] Methods: HEK 293 stably expressing MCH1R were maintained in Dulbeco's modified Eagle's medium (GIBCO/Life Technologies, Rockville, MD) supplemented with 2 mM glutamine and 10% dialyzed fetal bovine serum (HyClone, Logan, UT) at 37°C, 5% C02. Cells were harvested by 10' treatment with Versene (GIBCO/Life Technologies) followed by trituration, washing twice with cold (4°C) hybridoma medium (Serum/Protein free, with L- glutamine, sodium bicarbonate, MOPS buffer) (Sigma-Aldrich Corp, St. Louis, MO) and resuspended at 2 x 106 cells/mL in the same medium. The resuspended cells were loaded with the fluorescent calcium indicator Fura-2 by incubating with Fura-2AM (Molecular Probes, Eugene, OR) at 1.6 μM for 60' at room temperature. The loaded cells were then washed twice with hybridoma medium, adjusted to 2 x 105 cells/mL and kept at ambient temperature in a spinner flask under gentle stirring for up to 6 hours during the experiment . [0488] Receptor-stimulated intracellular calcium responses were detected in the flow-through detector cuvette of the HT- PS100 by monitoring increases in the ratio of Fura-2 fluorescence intensities R340/380 measured at alternating 340/380 nm excitation and 510 nm emission. [0489] Preliminary static experiments, conducted to determine the kinetics of MCHlR's dose response to MCH peptide, indicated the optimum time point to capture the maximum Ca++ transients was 30 s. No interference with DMSO was seen up to 1%. Based on these observations, subsequent experiments were conducted on the HT-PS100 to generate high resolution dose response curves, characterize agonist/antagonist properties, and evaluate antagonist potencies via Schild experiments. During HT- PS100 validation, reproducible EC50s for MCH of 10 nM were generated within a broad range of cell passage and harvest density. HT-PS100 gradient generation was calibrated with a standardized stock of fluorescein. [0490] Test compounds were screened for MCH1R activity in the HT-PS100 for both agonist and antagonist action. Agonist mode challenges were conducted at a maximum gradient concentration of 100 μM. Antagonist activity was tested by 30 s pre-incubation of cells at a compound concentration of 100 μM, with subsequent introduction of MCH at a concentration 5-fold of EC50 as determined in preliminary experiments. Compounds that showed inhibition of the MCH-induced Ca++ response were automatically tagged for re-interrogation, IC50 generation, and Schild analysis. [0491] Schild experiments were conducted on the HT-PS100 for selected compounds by 30 s pre-incubation of cells with antagonist compounds prior to administering MCH peptide. Several fixed concentrations of antagonist compounds were prepared in 10-fold increments, and presented to the cells 30 s before introducing a gradient of increasing MCH concentration. Values for compound pA2 were calculated by linear regression of Log (DR - 1) MCH EC50 as a function of Log (antagonist concentration), where DR is the dose ratio of MCH ECΞ0 values determined in the presence and absence of antagonist. [0492] The following compounds had Kj. values of 100 μM or less in the HT-PS100 assay: Compound Nos. . Of these, Compound Nos. had Ki values of 100 nM or less in this assay.
FLIPR® protocol : [0493] Materials: Pharmacological analysis was conducted using a FLIPR® device (Molecular Devices, Sunnyvale, CA) . CHOK1- Gqi cells were stably transfected with the rat MCHl receptor and maintained under G418 antibiotic pressure. FLIPR® assay buffer consisted of phenol red-free DMEM + 2.5 mM probenecid. MCH peptide (Amgen, Inc.) was reconstituted in assay buffer and served as the positive agonist control for all experiments. Test compounds were prepared as 10 mM stocks in 100% DMSO and diluted to a top end working concentration of 10 μM in 96 well black, flat bottom, collagen-I coated plates (Becton Dickinson, Bedford, MA) . [0494] Methods: CHOKl-Gqi cells stably expressing MCH1R were maintained in Dulbeco's modified Eagle's medium (GIBCO/Life Technologies, Rockville, MD) supplemented with 2 mM glutamine and 10% dialyzed fetal bovine serum (HyClone, Logan, UT) at 37 °C, 5% C02. Cells were harvested by 10' treatment with Versene (GIBCO/Life Technologies) followed by trituration, washing twice with cold (4°C) hybridoma medium (Serum/Protein free, with L- glutamine, sodium bicarbonate, MOPS buffer) (Sigma-Aldrich Corp, St.* Louis, MO) and replated onto 96 well black, flat bottom, collagen-I coated plates to a density of 10,000 cells/well. The cells were then loaded with the fluorescent calcium indicator Fura-2 (Molecular Probes, Eugene, OR) at 1.6 μM for 60' at room temperature. The loaded cells were then washed twice with 90 μl/well of wash buffer (1XHBSS, 20 mM HEPES, 2.5 mM probenecid) . [0495] Receptor-stimulated intracellular calcium responses were detected using FLIPR® by monitoring increases in the Fura-2 fluorescence response. [0496] Test compounds were screened for MCH1R activity in the FLIPR® for both agonist and antagonist action. Agonist mode challenges were conducted at a maximum gradient concentration of 1 μM. Antagonist activity was tested by 10 min pre-incubation of cells at a compound concentration of defined to be 300X the EC50 of MCH (typically 1 μM) , with subsequent introduction of MCH at a concentration 5-fold of EC50 as determined in preliminary experiments. Compounds that showed inhibition of MCH induced MCH1R dependant Ca++ responses were automatically tagged for re- interogation, IC50 generation, and Schild analysis. [0497] Schild experiments were conducted on the FLIPR® for selected compounds by co-administering antagonist compounds together with MCH peptide. Several fixed concentrations of antagonist compounds were prepared in 10-fold increments, and presented to the cells in a gradient of increasing MCH concentration. Values for compound pA2 were calculated by linear regression of MCH EC50s as a function Of antagonist concentration . [0498] The following compounds had Ki values of 100 μM or less in the rMCH FLIPR® assay: Compound Nos. 1, 5, 6, 15, 22, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 51, 53, 54, 55, 56, 57, 58, 59, and 64. Of these, Compound Nos. 1, 6, 15, 31, 32, 38, 39, 40, and 41 had Ki values of 100 nM or less in this assay. [0499] The following compounds had Ki values of 100 μM or less in the hMCH FLIPR® assay: Compound Nos. 1, 5, 6, 34, 35, 36, 37, 38, 40, 41, 51, 52, 53, 54, 55, 56, 57, 58, 59, and 64. Of these, Compound Nos. 1, 6, 34, 35, 38, 40, 41, 51, 56, and 57 had Ki values of 100 nM or less in this assay.
Example 24 Ligand Binding Assay
[0500] Binding assays were determined as described below using mouse, rat or human MCH 1 receptors (mMCHlR, rMCHIR, and hMCHIR, respectively) expressed in HEK 293; IC50 values were calculated. [0501] Binding assays were performed in 96-well U-bottom plates. Membranes (100 μg tissue) were incubated at 30°C for 90 minutes in assay buffer with various peptides in the presence of 0.2 nM 1251 native-MCH (Perkin-Elmer Life Sciences, Boston, MA) in 100 μL total volume. Non-specific binding was assessed in the presence of 1 μM cold native-MCH. The reaction was terminated by rapid filtration through Unfilter-96 GF/C glass fiber filter plates (FilterMate® 196 Harvester, Packard Instrument Co., Meriden, CT) pre-sόaked in PBS/O.5% BSA, followed by three washes with 300 μL ice-cold water. Bound radioactivity was determined using a TopCount® microplate scintillation and luminescence counter (Packard Instrument Co., Meriden, CT) . Nonlinear regression analyses of drug concentration curves were performed using GraphPad Prism® (GraphPad Software, Inc., San Diego, CA) . [0502] The following compounds had ICS0 values of 100 μM or less in the rMCH assay: Compound Nos. 1, 10, 12, 13, 15, 16, 17, 18, 22, 27, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 63, 64, 65, and 66 . Of these, Compound Nos. 1, 31, 38, 39, 40, 41, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, and 66 had IC50 values of 100 nM or less in the rMCH assay. [0503] The following compounds had IC50 values of 100 μM or less in the hMCH assay: Compound Nos. 1, 5, 6, 8, 10, 12, 13, 15, 16, 17, 18, 20, 22, 27, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 58, 59, 64, 65, and 66 . Of these, Compound Nos. 1, 6, 31, 32, 33, 34, 36, 37, 38, 39, 40, 41, 58, 59, and 66 had IC50 values of 100 nM or less in the hMCH assay. [0504] In view of the above, it will be seen that the several objects of the invention are achieved. [0505] The above description of the embodiments and examples are intended only to acquaint others skilled in the art with the invention, its principles, and its practical application, so that others skilled in the art may adapt and apply the invention in its numerous forms, as may be best suited to the requirements of a particular use. The present invention, therefore, is not limited to the above embodiments, and may be variously modified. [0506] With reference to the use of the word(s) "comprise" or "comprises" or "comprising" or "including" or "having" in the above description and/or in the following claims, it should be noted that unless the context requires otherwise, those words are used on the basis and clear understanding that they are to be interpreted inclusively, rather than exclusively, and that each of those words is to be so interpreted in construing the above description and/or the following claims. When introducing elements of the present invention or the preferred embodiment (s) thereof, the articles "a," "an," "the," and "said" are intended to mean that there are one or more of the elements. [0507] In view of the above, it will be seen that the several objects of the invention are achieved and other advantageous results attained. [0508] As various changes could be made in the above compounds and methods without departing from the scope of the invention, it is intended that all matter contained in the above description shall be interpreted as illustrative and not in a limiting sense. [0509] The entire texts of all U.S. Patents and other references cited herein are hereby incorporated by reference into this patent .

Claims

What is claimed is:
1. A compound of Formula I , or a pharmaceutically- acceptable salt, tautomer or prodrug thereof:
Figure imgf000259_0001
wherein: W is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano; X is selected from the group consisting of -OR1, -NR1R10, and -SR1; Y is selected from the group consisting of hydrogen, -N(R7)C(0)NR2R8, -N(R7)C(0)OR2, -N (R7) C (O) R2, -N (R7) S02R2, and -NR2R7; Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(O)-, -C(0)N(R9)-, and -N (R12) C (O) N (R9) - ; R1 is selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, and heteroarylalkyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; R2 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, arylcycloalkyl, and heteroarylalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; R3 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano; R4 is selected from the group consisting of a bond, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and heteroarylalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, alkoxycarbonyl, and halo; R5 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; Rs is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R7 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano; R8 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; R9 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R10 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano; R11 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano; and R12 is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, aralkyl, halo, alkoxy, hydroxyalkyl, alkoxyalkyl, aryloxy, carboxyl, carboxyalkyl, and cyano .
2. The compound, pharmaceutically-acceptable salt or tautomer of claim 1, wherein: W is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl, lower aralkyl, heteroaryl, and lower heteroarylalkyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, lower arylcycloalkyl, and lower heteroarylalkyl , or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R3 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower heteroarylalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, lower alkoxycarbonyl, and halo; R5 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R5 together with Rs and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R6 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R7 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; R8 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; R9 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R10 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; R11 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano; and R12 is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, halo, lower alkoxy, lower hydroxyalkyl, lower alkoxyalkyl, aryloxy, carboxyl, lower carboxyalkyl, and cyano.
3. The compound, pharmaceutically-acceptable salt or tautomer of claim 2, wherein: W is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl, carboxyhexyl, and cyano; R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl , benzodioxolyl , benzyl , diphenylmethyl , triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl , cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl , phenylethenyl, phenylpropenyl , phenylallyl, phenylbutenyl , phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenyleye1opentyl , phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl , tetrahydroindolyl, dihydroindolyl , indolinyl, octahydroquinolinyl, hexahydroquinolinyl , tetrahydroquinolinyl , dihydroquinolinyl , and quinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R3 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl , tetrahydronaphthyl , biphenyl , benzyl , diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano; R4 is selected from the group consisting of a bond, methyl , ethyl , propyl , butyl , pentyl , hexyl , ethenyl , propenyl, allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl , cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl , ethoxycarbonyl , propoxycarbonyl , butoxycarbonyl , pentyloxycarbonyl, hexyloxycarbonyl, chloro, bromo, and fluoro; R5 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl , butoxypropyl , butoxybutyl , butoxypentyl , pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano, or R5 together with Rδ and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R6 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl , butoxypentyl , pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , carboxyhexyl , and cyano, or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R7 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl , ethoxypentyl , propoxymethyl, propoxyethyl, propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl , butoxypropyl , butoxybutyl , butoxypentyl , pentoxymethyl , pentoxyethyl , pentoxypropyl , pentoxybutyl , pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , carboxyhexyl , and cyano; R8 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl , pentoxyethyl , pentoxypropyl , pentoxybutyl , pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , carboxyhexyl , and cyano, or R8 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; R9 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , carboxyhexyl , and cyano, or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R10 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , carboxyhexyl , and cyano; R11 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , carboxyhexyl , and cyano; and R12 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , carboxyhexyl , and cyano .
4. The compound, pharmaceutically-acceptable salt or tautomer of claim 1, wherein X is -OR1.
5. The compound, pharmaceutically-acceptable salt or tautomer of claim 2, wherein X is -OR1.
6. The compound, pharmaceutically-acceptable salt or tautomer of claim 3, wherein X is -OR1.
7. The compound, pharmaceutically-acceptable salt, tautomer or prodrug of claim 1 , selected from the group of compounds consisting of 4- [ (3, 4-dimethylphenyl) oxy] -3-{ [ (phenylamino) carbonyl] amino} - N- (2- (1-pyrrolidinyl) ethyl) benzamide,
4- [ (3, 4 -dimethylphenyl) oxy] -3- [ (3-phenylpropanoyl) amino] -N- (2- (1-pyrrolidinyl) ethyl) benzamide ,
4- [ (3 , 4-dimethylphenyl) oxy] -3 - ({ [ (phenylmethyl) amino] carbonyl} amino) -N- (2- (1- pyrrolidinyl) ethyl) benzamide,
4- (phenyloxy) -N- (2- (1-pyrrolidinyl) ethyl) benzamide,
3-acetylamino-4- (3 , 4-dimethylphenoxy) -N- (2-pyrrolidin-l-yl- ethyl) benzamide ,
4- (3 ,4-dimethylphenoxy) -3-propionylamino-N- (2-pyrrolidin-l-yl- ethyl) benzamide,
3- (3-cyclopentylpropionylamino) -4- (3 , 4-dimethylphenoxy) -N- (2- pyrrolidin- 1-yl-ethyl) benzamide,
4- (3 ,4 -dimethylphenoxy) -3-phenylacetylamino-N- (2-pyrrolidin-l- yl-ethyl) benzamide,
4- (3 , 4-dimethylphenoxy) -3- (3-phenyl-acryloylamino) -N- (2- pyrrolidin- 1-yl-ethyl) benzamide,
4- (3 , 4-dimethylphenoxy) -3- [ (2 -phenyl- cyclopropanecarbonyl) amino] -N- (2-pyrrolidin-l-yl- ethyl) benzamide ,
naphthalene-2 -carboxylic acid [2- (3 , 4-dimethylphenoxy) -5- (2- pyrrolidin-1-yl-ethylcarbamoyl) phenyl] amide,
4- (3 ,4 -dimethylphenoxy) -3- (3-ethylureido) -N- (2-pyrrolidin-l- yl-ethyl) benzamide,
N- (2-aminoethyl) -4- (3 , 4-dimethylphenoxy) -3- (3- phenylpropionylamino) benzamide,
4-methoxy-3- (3-phenylpropionylamino) -N- (2-pyrrolidin-l-yl- ethyl) benzamide , 4- (naphthalen-2-yl-oxy) -3- (3-phenylpropionylamino) -N- (2- pyrrolidin-1-yl-ethyl) benzamide,
4- (3, 4 -dimethylphenoxy) -3- [3- (2-methoxyphenyl) ureido] -N- (2- pyrrolidin-1-yl-ethyl) benzamide,
3- [3- (2,4-dichlorophenyl)ureido] -4- (3 , 4-dimethylphenoxy) -N- (2- pyrrolidin- 1-yl-ethyl) benzamide,
4- (3 , -dimethylphenoxy) -3- [3- (4 -phenoxyphenyl) ureido] -N- (2- pyrrolidin- 1-yl-ethyl) benzamide,
3- (3 -biphenyl-4 -yl-ureido) -4- (3 , 4-dimethylphenoxy) -N- (2- pyrrolidin-1-yl-ethyl) benzamide,
4- (3 , 4-dimethylphenoxy) -3- [3- (4-isopropylphenyl) ureido] -N- (2- pyrrolidin-1-yl-ethyl) benzamide,
4- (3 ,4 -dimethylphenoxy) -3- [3- (2 , 6-dimethylphenyl) ureido] -N- (2- pyrrolidin-1-yl-ethyl) benzamide,
4- (3 , 4-dimethylphenoxy) -3- (3 -naphthalen-1-yl-ureido) -N- (2- pyrrolidin- 1-yl-ethyl) benzamide,
3- [3- (2, 6-diisopropylphenyl) ureido] -4- (3 , 4-dimethylphenoxy) -N- (2 -pyrrolidin-1-yl-ethyl) benzamide,
3- [3- (4-bromophenyl) ureido] -4- (3 , 4-dimethylphenoxy) -N- (2- pyrrolidin-1-yl-ethyl) benzamide,
4- (3 ,4 -dimethylphenoxy) -3- [3- (3-fluorophenyl) ureido] -N- (2- pyrrolidin-1-yl-ethyl) benzamide ,
4- (3 ,4 -dimethylphenoxy) -3- [3- (3 -methoxyphenyl) ureido] -N- (2- pyrrolidin-1-yl-ethyl) benzamide,
3- [3- (2-chlorophenyl) ureido] -4- (3 , 4-dimethylphenoxy) -N- (2- pyrrolidin-1-yl-ethyl) benzamide,
4- (3 , -dimethylphenoxy) -3- (3 , 3 -diphenylureido) -N- (2- pyrrolidin-1-yl-ethyl) benzamide , 4- (3, 4-dimethylphenoxy) -3- (3 -methyl-3 -phenylureido) -N- (2- pyrrolidin-1-yl-ethyl) benzamide ,
1, 3 -dihydroisoindole-2 -carboxylic acid [2- (3,4- dimethylphenoxy) -5- (2 -pyrrolidin-1-yl- ethylcarbamoyl) phenyl] amide,
4- (4-fluoro-3-methylphenoxy) -3- [3- (3-fluorophenyl) ureido] -N- (2 -pyrrolidin- 1-yl-ethyl) benzamide,
4- (3 ,4-dichlorophenoxy) -3- [3- (3-fluorophenyl) ureido] -N- (2- pyrrolidin-1-yl-ethyl) benzamide ,
4- (3 , 4-difluorophenoxy) -3- [3- (3-fluorophenyl) ureido] -N- (2- pyrrolidin- 1-yl-ethyl) benzamide,
4- (4-fluorophenoxy) -3- [3- (3-fluorophenyl) ureido] -N- (2- pyrrolidin-1-yl-ethyl) benzamide,
4- (3-fluorophenoxy) -3- [3- (3-fluorophenyl) ureido] -N- (2- pyrrolidin-1-yl-ethyl) benzamide,
3- [3- (3-fluorophenyl) ureido] -N- (2-pyrrolidin-l-yl-ethyl) -4-p- tolyloxybenzamide ,
3- [3- (3 -fluorophenyl) ureido] -N- (2-pyrrolidin-l-yl-ethyl) -4-m- tolyloxybenzamide,
3- [3- (3, 5-difluorophenyl) ureido] -4- (3 , 4-dimethylphenoxy) -N- (2- pyrrolidin- 1-yl -ethyl) benzamide ,
3- [3- (3, 5-dichlorophenyl) ureido] -4- (3 , 4-dimethylphenoxy) -N- (2- pyrrolidin- 1-yl-ethyl) benzamide,
3- [3- (3-fluorophenyl) ureido] -4-phenoxy-N- (2-pyrrolidin-l-yl- ethyl) benzamide,
1- [2- (3, 4-dimethylphenoxy) -5- (2-pyrrolidin-l-yl- methylpyrrolidine-1-carbonyl) phenyl] -3 -phenylurea,
1- {2- (3 , 4-dimethylphenoxy) -5- [ (2-pyrrolidin-l-yl-ethylamino) - methyl] phenyl} -3- (3-fluorophenyl) urea, 1- [2- (3 , 4-dimethylphenoxy) -5- (2 -pyrrolidin-1-yl- methylpyrrolidine-1-carbonyl) phenyl] -3 -phenylurea, and
4- (3 , 4-dichlorophenoxy) -3- [3- (3 , 5-difluorophenyl) ureido] -N- (2- pyrrolidin-1-yl-ethyl) benzamide .
8. A compound of claim 1, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein the compound corresponds to Formula II
Figure imgf000275_0001
wherein: W is selected from the group consisting of hydrogen, hydroxy, alkyl, and alkoxy; X is selected from the group consisting of -OR1, -NR1R10, and -SR1; Y is selected from the group consisting of hydrogen, -N(R7)C(0)NR2R8, -N(R7)C(0)OR2, -N (R7) C (0) R2, -N(R7)S02R2, and -NR2R7 ; Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -C(0)-, -CH2N(R9)-, and -N (R12) C (O) N (R9) - ; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; R2 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; R4 .is selected from the group consisting of a bond, alkyl, alkenyl, and cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, and halo; Rs is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R5 together with Rδ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R6 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or Rs together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R7 is selected from the group consisting of hydrogen, alkyl, and aryl; R8 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, wherein R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; R9 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R10 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl; and R12 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl .
9. The compound, pharmaceutically-acceptable salt or tautomer of claim 8, wherein: W is selected from the group consisting of hydrogen, hydroxy, lower alkyl, and lower alkoxy; R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo; R5 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R6 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R7 is selected from the group consisting of hydrogen, lower alkyl, and aryl, R8 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; R9 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R10 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl; and R12 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl.
10. The compound, pharmaceutically-acceptable salt or tautomer of claim 9, wherein: W is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, and hexyloxy; R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl , cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl , cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl , cyclohexylpentyl , phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl , tetrahydroisoindolyl , dihydroisoindolyl, isoindolinyl, hexahydroindolyl , tetrahydroindolyl , dihydroindolyl , indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R3 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl , hydroxybutyl, hydroxypentyl , hydroxyhexyl , methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl, carboxypentyl , carboxyhexyl , and cyano; R4 is selected from the group consisting of a bond, methyl , ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl , hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl , cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl , phenylethenyl , phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl , ethoxycarbonyl , propoxycarbonyl , butoxycarbonyl, pentyloxycarbonyl , hexyloxycarbonyl, chloro, bromo, and fluoro; RΞ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl , pentoxypropyl , pentoxybutyl , and pentoxypentyl , or R5 together with R6 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; Rs is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or Rs together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R7 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl , and biphenyl ; R8 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl , pentoxymethyl , pentoxyethyl , pentoxypropyl , pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl , or R8 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; R9 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl , or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R10 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl , pentoxypentyl , carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl ; and R12 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl , pentoxypentyl , carboxymethyl , carboxyethyl , carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl
11. A compound of claim 1, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein the compound corresponds to Formula III
Figure imgf000284_0001
wherein: X is selected from the group consisting of -OR1 and -SR1; Y is selected from the group consisting of hydrogen, -N(R7)C(0)NR2R8, -N(R7)C(0)OR2, -N (R7) C (0) R2, -N(R7)S02R2, and -NR2R7; Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -CH2N(R9)-, and -NHC(0)NR9-; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; R2 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; R4 is selected from the group consisting of a bond, alkyl, alkenyl, and cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, and halo; R5 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; Rδ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R7 is selected from the group consisting of hydrogen, alkyl , and aryl ; R8 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; R9 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R10 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl; and R12 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl .
12. The compound, pharmaceutically-acceptable salt or tautomer of claim 11, wherein: R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo; R5 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R6 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R7 is selected from the group consisting of hydrogen, lower alkyl, and aryl; R8 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; R9 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R10 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl; and R12 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl.
13. The compound, pharmaceutically-acceptable salt or tautomer of claim 12, wherein: R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl , cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl , cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl , cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl , or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl , tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl , tetrahydroindolyl , dihydroindolyl , indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl , dihydroquinolinyl, and quinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R3 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , carboxyhexyl , and cyano; R4 is selected from the group consisting of a bond, methyl , ethyl , propyl , butyl , pentyl , hexyl , ethenyl , propenyl, allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl , cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl , phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl , ethoxycarbonyl , propoxycarbonyl , butoxycarbonyl , pentyloxycarbonyl, hexyloxycarbonyl, chloro, bromo, and fluoro; R5 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R5 together with R6 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R6 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl , pentoxypropyl , pentoxybutyl , and pentoxypentyl , or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R7 is selected from the group consisting of hydrogen, methyl , ethyl , propyl , butyl , pentyl , hexyl , phenyl , naphthyl , tetrahydronaphthyl, and biphenyl; R8 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl , pentoxymethyl , pentoxyethyl , pentoxypropyl , pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R8 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; R9 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl , ethoxybutyl, ethoxypentyl, propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl , pentoxypentyl , carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl , or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R10 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl, ethoxybutyl, ethoxypentyl, propoxymethyl, propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl , pentoxymethyl , pentoxyethyl , pentoxypropyl , pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl ; and R12 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl .
14. A compound of claim 1, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein the compound corresponds to Formula IV
Figure imgf000292_0001
wherein: X is selected from the group consisting of -OR1 and -SR1; Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -CH2N(R9)-, and -NHC (O) NR9- ; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; R2 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; R4 is selected from the group consisting of a bond, alkyl, alkenyl, and cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, and halo ; R5 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R6 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R7 is selected from the group consisting of hydrogen, alkyl, and aryl, R8 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; R9 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R10 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl; and R12 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl .
15. The compound, pharmaceutically-acceptable salt or tautomer of claim 14, wherein: R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo; R5 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R6 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R7 is selected from the group consisting of hydrogen, lower alkyl, and aryl; R8 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, wherein R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; R9 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R10 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl; and R12 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl.
16. The compound, pharmaceutically-acceptable salt or tautomer of claim 15, wherein: R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl , cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl , or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl , tetrahydroindolyl , dihydroindolyl , indolinyl , octahydroquinolinyl , hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R3 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, chloro, bromo, fluoro, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, hydroxymethyl, hydroxyethyl, hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl , butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, carboxyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, carboxyhexyl, and cyano; R4 is selected from the group consisting of a bond, methyl , ethyl , propyl , butyl , pentyl , hexyl , ethenyl , propenyl, allyl, butenyl , pentenyl, acetylenyl, propynyl , butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl , cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl , phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl , ethoxycarbonyl , propoxycarbonyl , butoxycarbonyl , pentyloxycarbonyl , hexyloxycarbonyl, chloro, bromo, and fluoro; R5 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl , pentoxypropyl , pentoxybutyl , and pentoxypentyl , or R5 together with R6 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R6 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl , pentoxypropyl , pentoxybutyl , and pentoxypentyl , or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R7 is selected from the group consisting of hydrogen, methyl , ethyl , propyl , butyl , pentyl , hexyl , phenyl , naphthyl , tetrahydronaphthyl, and biphenyl; R8 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R8 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; R9 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl , or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R10 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl , pentoxypentyl , carboxymethyl , carboxyethyl , carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl ; and R12 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl , pentoxymethyl , pentoxyethyl , pentoxypropyl , pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl
17. A compound of claim 1, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein the compound corresponds to Formula V
Figure imgf000301_0001
wherein: X is selected from the group consisting of -OR1 and -SR1; Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -CH2N(R9)-, and -NHC (O) NR9- ; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; R2 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; R4 is selected from the group consisting of a bond, alkyl, alkenyl, and cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, and halo; R5 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; Rs is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R7 is selected from the group consisting of hydrogen, alkyl , and aryl ; R8 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl , or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; and R9 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring.
18. The compound, pharmaceutically-acceptable salt or tautomer of claim 17, wherein: R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo; R5 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl , or R5 together with Rs and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; Rs is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R7 is selected from the group consisting of hydrogen, lower alkyl, and aryl; R8 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; and R9 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring.
19. The compound, pharmaceutically-acceptable salt or tautomer of claim 18, wherein: R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl , phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl , tetrahydroindolyl, dihydroindolyl , indolinyl, octahydroquinolinyl , hexahydroquinolinyl , tetrahydroquinolinyl , dihydroquinolinyl, and quinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R4 is selected from the group consisting of a bond, methyl , ethyl , propyl , butyl , pentyl , hexyl , ethenyl , propenyl , allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl , cyclopropylethyl , cyclopropylpropyl , cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl , cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl , phenylethenyl , phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl , ethoxycarbonyl , propoxycarbonyl , butoxycarbonyl , pentyloxycarbonyl , hexyloxycarbonyl, chloro, bromo, and fluoro; R5 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R5 together with R6 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R6 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl , biphenyl , benzyl , diphenylmethyl , triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R7 is selected from the group consisting of hydrogen, methyl , ethyl , propyl , butyl , pentyl , hexyl , phenyl , naphthyl , tetrahydronaphthyl, and biphenyl; R8 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R8 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; and R9 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxypentyl, and carboxyhexyl, or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring.
20. A compound of claim 1, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein the compound corresponds to Formula VI
Figure imgf000308_0001
wherein: X is selected from the group consisting of -OR1 and -SR1; Z is selected from the group consisting of -CH=CH-, -CH2N(R9)-, -CH2N(R9)-, and -NHC (O)NR9- ; R1 is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; R2 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, carboxyl, aryloxy, oxo, and halo; R4 is selected from the group consisting of a bond, alkyl, alkenyl, and cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, and halo; R5 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R6 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, and alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R7 is selected from the group consisting of hydrogen, alkyl, and aryl; and R9 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, and carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring.
21. The compound, pharmaceutically-acceptable salt or tautomer of claim 20, wherein: R1 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, and heteroaryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R2 is selected from the group consisting of lower alkyl, lower cycloalkyl, aryl, heteroaryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, carboxyl, aryloxy, oxo, and halo; R4 is selected from the group consisting of a bond, lower alkyl, lower alkenyl, and lower cycloalkyl, or R4 together with R9 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, and halo; R5 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or Rs together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R6 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, and lower alkoxyalkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; R7 is selected from the group consisting of hydrogen, lower alkyl, and aryl; R8 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system; and R9 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, aryl, lower aralkyl, lower hydroxyalkyl, lower alkoxyalkyl, and lower carboxyalkyl, or R9 together with R4 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring.
22. The compound, pharmaceutically-acceptable salt or tautomer of claim 21, wherein: R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, and benzodioxolyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl, phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, phenylcyclopropyl, phenylcyclobutyl, phenylcyclopentyl, phenylcyclohexyl, biphenylcyclopropyl, biphenylcyclobutyl, biphenylcyclopentyl, biphenylcyclohexyl, naphthylcyclopropyl, naphthylcyclobutyl, naphthylcyclopentyl, naphthylcyclohexyl, or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of hexahydroisoindolyl, tetrahydroisoindolyl, dihydroisoindolyl, isoindolinyl, hexahydroindolyl , tetrahydroindolyl, dihydroindolyl , indolinyl, octahydroquinolinyl, hexahydroquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, and quinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, chloro, bromo, and fluoro; R4 is selected from the group consisting of a bond, methyl , ethyl , propyl , butyl , pentyl , hexyl , ethenyl , propenyl, allyl, butenyl, pentenyl, acetylenyl, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxazolyl, indolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxatriazolyl, dioxazole, tetrazolyl, benzodioxolyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclobutylmethyl, cyclobutylethyl , cyclobutylpropyl, cyclobutylbutyl, cyclobutylpenyyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclopentylbutyl, cyclopentylpentyl , cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cyclohexylpentyl , phenylethenyl, phenylpropenyl, phenylallyl, phenylbutenyl, phenylpentenyl, or R4 together with R9 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring, wherein R4 or the ring formed with R9 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, carboxyl, phenoxy, naphthyloxy, tetrahydronaphthyloxy, biphenylyloxy, oxo, methoxycarbonyl , ethoxycarbonyl , propoxycarbonyl , butoxycarbonyl , pentyloxycarbonyl , hexyloxycarbonyl, chloro, bromo, and fluoro; R5 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R5 together with R6 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; Rδ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, methoxymethyl, methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, and pentoxypentyl, or R6 together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R7 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, naphthyl, tetrahydronaphthyl, and biphenyl; R8 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl , methoxypentyl , ethoxymethyl , ethoxyethyl , ethoxypropyl , ethoxybutyl , ethoxypentyl , propoxymethyl , propoxyethyl , propoxypropyl , propoxybutyl , propoxypentyl , butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl , or R8 together with R2 and the nitrogen to which they are attached may form an isoindolinyl ring; and R9 is selected from the group consisting of hydrogen, methyl , ethyl , propyl , butyl , pentyl , hexyl , cyclopropyl , cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl, hydroxymethyl, hydroxyethyl , hydroxypropyl , hydroxybutyl , hydroxypentyl , hydroxyhexyl , methoxymethyl , methoxyethyl , methoxypropyl , methoxybutyl, methoxypentyl, ethoxymethyl, ethoxyethyl, ethoxypropyl , ethoxybutyl , ethoxypentyl ,° propoxymethyl , propoxyethyl, propoxypropyl, propoxybutyl, propoxypentyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl, butoxypentyl, pentoxymethyl, pentoxyethyl, pentoxypropyl, pentoxybutyl, pentoxypentyl, carboxymethyl, carboxyethyl, carboxypropyl , carboxybutyl , carboxypentyl , and carboxyhexyl , or R9 together with R4 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring.
23. A compound of claim 1, or a pharmaceutically- acceptable salt, tautomer or prodrug thereof, wherein the compound corresponds to Formula VII
Figure imgf000315_0001
wherein: R1 is selected from the group consisting of cycloalkyl and aryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, and halo; R2 is selected from the group consisting of alkyl, aryl, aralkyl, cycloalkylalkyl, aralkenyl, and arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, aryloxy, and halo; R5 is selected from the group consisting of hydrogen and alkyl, or R5 together with R6 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; Rs is selected from the group consisting of hydrogen and alkyl, or R6 together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; and R8 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, and aryl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system.
24. The compound, pharmaceutically-acceptable salt or tautomer of claim 23, wherein: R1 is selected from the group consisting of lower cycloalkyl and aryl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, and halo; R2 is selected from the group consisting of lower alkyl, aryl, lower aralkyl, lower cycloalkylalkyl, lower aralkenyl, and lower arylcycloalkyl, or R2 together with R8 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system, wherein R2 or the unsaturated fused heterocyclic ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, aryloxy, and halo;
R5 is selected from the group consisting of hydrogen and lower alkyl, or R5 together with Rδ and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; Rδ is selected from the group consisting of hydrogen and lower alkyl, or Rδ together with R5 and the nitrogen to which they are attached may form a saturated 5- or 6-membered heterocyclic ring; and R8 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, and aryl, or R8 together with R2 and the nitrogen to which they are attached may form an unsaturated fused heterocyclic ring system.
25. The compound, pharmaceutically-acceptable salt or tautomer of claim 24, wherein: R1 is selected from the group consisting of cyclopentyl, cyclohexyl, phenyl, naphthyl, and biphenyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, hydroxy, methoxy, ethoxy, propoxy, chloro, bromo, and fluoro; R2 is selected from the group consisting of methyl, ethyl, propyl, butyl, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, benzyl, phenylethyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, phenylethenyl, phenylpropenyl, phenyleye1opropyl , biphenyleye1opropy1 , and naphthylcyclopropyl, or R2 together with R8 and the nitrogen to which they are attached may form a ring selected from the group consisting of dihydroisoindolyl, dihydroindolyl , tetrahydroisoquinolinyl, and tetrahydroquinolinyl, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, hydroxy, methoxy, ethoxy, propoxy, phenoxy, naphthyloxy, biphenylyloxy, chloro, bromo, and fluoro; R5 is selected from the group consisting of hydrogen, methyl , ethyl , propyl , butyl , pentyl , and hexyl , or R5 together with R6 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; R6 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, and hexyl, or Rδ together with R5 and the nitrogen to which they are attached may form a pyrrolidinyl or a piperidinyl ring; and R8 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, and biphenyl, or R8 together with R2 and the nitrogen to which they are attached may form a ring selected from the group consisting of dihydroisoindolyl, dihydroindolyl, tetrahydroisoquinolinyl, and tetrahydroquinolinyl .
26. The compound, pharmaceutically-acceptable salt or tautomer of claim 25, wherein: R1 is selected from the group consisting of phenyl, and naphthyl, wherein R1 is optionally substituted with one or more substituents selected from the group consisting of methyl, chloro, and fluoro; R2 is selected from the group consisting of methyl, ethyl, phenyl, naphthyl, biphenyl, benzyl, phenylethyl, cyclopentylethyl, phenylethenyl , phenylcyclopropyl, or R2 together with R8 and the nitrogen to which they are attached may form a dihydroisoindolyl ring, wherein R2 or the ring formed with R8 is optionally substituted with one or more substituents selected from the group consisting of methyl, propyl, methoxy, phenoxy, chloro, bromo, and fluoro; R5 is hydrogen or R5 together with R6 and the nitrogen to which they are attached form a pyrrolidinyl ring; R6 is hydrogen or R6 together with R5 and the nitrogen to which they are attached form a pyrrolidinyl ring; and R8 is selected from the group consisting of hydrogen, methyl, and phenyl, or R8 together with R2 and the nitrogen to which they are attached may form a dihydroisoindolyl ring.
27. A pharmaceutical composition comprising a compound, pharmaceutically-acceptable salt, tautomer or prodrug according to any one of claims 1-26, and a pharmaceutically acceptable carrier, adjuvant, or diluent.
28. A method of treating or preventing a melanin concentrating hormone-mediated disorder in a subject, the method comprising administering to a subject in need of such treatment or prevention a compound, pharmaceutically- acceptable salt, tautomer or prodrug according to any one of claims 1-26, or the pharmaceutical composition of claim 27.
29. A method of treating or preventing a condition selected from the group consisting of feeding disorders, sexual disorders, reproductive disorders, depression, anxiety, epileptic seizure, hypertension, cerebral hemorrhage, congestive heart failure, and sleep disturbances, comprising administering to a subject in need of such treatment or prevention a compound, pharmaceutically-acceptable salt, tautomer or prodrug according to any one of claims 1-26, or the pharmaceutical composition of claim 27.
30. The method of claim 29 wherein the condition being treated or prevented is a feeding disorder.
31. The method of claim 30 wherein the feeding disorder is selected from the group consisting of obesity, bulimia and bulimia nervosa.
32. The method of treating or preventing obesity, comprising administering to a subject in need of such treatment or prevention the compound, pharmaceutically- acceptable salt, tautomer or prodrug of any of claims 1-26.
PCT/US2004/025970 2003-08-13 2004-08-11 Melanin concentrating hormone receptor antagonists WO2005019240A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP04780754A EP1654225A4 (en) 2003-08-13 2004-08-11 Melanin concentrating hormone receptor antagonists
CA002534428A CA2534428A1 (en) 2003-08-13 2004-08-11 Melanin concentrating hormone receptor antagonists
JP2006523322A JP2007502283A (en) 2003-08-13 2004-08-11 Melanin-concentrating hormone receptor antagonist
MXPA06001638A MXPA06001638A (en) 2003-08-13 2004-08-11 Melanin concentrating hormone receptor antagonists.
AU2004266228A AU2004266228A1 (en) 2003-08-13 2004-08-11 Melanin concentrating hormone receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49485503P 2003-08-13 2003-08-13
US60/494,855 2003-08-13

Publications (2)

Publication Number Publication Date
WO2005019240A2 true WO2005019240A2 (en) 2005-03-03
WO2005019240A3 WO2005019240A3 (en) 2005-05-06

Family

ID=34215905

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/025970 WO2005019240A2 (en) 2003-08-13 2004-08-11 Melanin concentrating hormone receptor antagonists

Country Status (7)

Country Link
US (1) US20050256161A1 (en)
EP (1) EP1654225A4 (en)
JP (1) JP2007502283A (en)
AU (1) AU2004266228A1 (en)
CA (1) CA2534428A1 (en)
MX (1) MXPA06001638A (en)
WO (1) WO2005019240A2 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
JP2008536824A (en) * 2005-04-01 2008-09-11 イーライ リリー アンド カンパニー Histamine H3 receptor drug, formulation and therapeutic use
US7504412B2 (en) 2003-08-15 2009-03-17 Banyu Pharmaceuticals, Co., Ltd. Imidazopyridine derivatives
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US7803816B2 (en) 2005-09-30 2010-09-28 Hoffmann-La Roche Inc. MCH receptor antagonists
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US9302989B2 (en) 2010-11-15 2016-04-05 Abbvie Inc. NAMPT and rock inhibitors
WO2016166684A1 (en) 2015-04-15 2016-10-20 Richter Gedeon Nyrt. Indole derivatives

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550499B2 (en) * 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
KR20070100894A (en) * 2005-01-19 2007-10-12 브리스톨-마이어스 스큅 컴퍼니 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
US7700620B2 (en) * 2005-06-27 2010-04-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE602006021306D1 (en) * 2005-06-27 2011-05-26 Bristol Myers Squibb Co
US7714002B2 (en) * 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
ATE502924T1 (en) * 2005-06-27 2011-04-15 Bristol Myers Squibb Co LINEAR UREA MIMETIC ANTAGONISTS OF THE P2Y1 RECEPTOR FOR THE TREATMENT OF THROMBOSIS
US7960569B2 (en) * 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
RU2020123398A (en) * 2015-04-17 2020-09-18 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Compounds useful as pesticides and intermediates, compositions and methods related thereto
WO2017007634A1 (en) * 2015-07-06 2017-01-12 The Board Of Regents Of The University Of Texas System Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers
NZ753358A (en) 2016-10-12 2022-07-29 Corteva Agriscience Llc Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2730174C2 (en) * 1977-07-04 1981-12-10 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren Aminobenzoic acid derivatives and medicaments containing such aminobenzoic acid derivatives
EP0127124A3 (en) * 1983-05-23 1987-04-08 Usv Pharmaceutical Corporation Compounds for treating hypertension
GB0001447D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
JP4025200B2 (en) * 2000-12-22 2007-12-19 シェーリング コーポレイション Piperidine MCH antagonists and their use in the treatment of obesity
DE10123958A1 (en) * 2001-05-17 2002-11-28 Aventis Pharma Gmbh Identifying ligands for G protein-coupled receptors, useful for treating cardiovascular disease, by using calcium-sensitive fluorophores in cells expressing G alpha proteins
PE20021091A1 (en) * 2001-05-25 2003-02-04 Aventis Pharma Gmbh DERIVATIVES OF PHENYLUREA SUBSTITUTED WITH CARBONAMIDE AND PROCEDURE FOR THEIR PREPARATION
US6552188B2 (en) * 2001-06-29 2003-04-22 Kowa Co., Ltd. Unsymmetrical cyclic diamine compound
DE10139416A1 (en) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituted aromatic bicycles, process for their preparation and their use as medicaments
CA2468015A1 (en) * 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
US6818772B2 (en) * 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
AU2003226927A1 (en) * 2002-04-09 2003-10-27 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
AU2003226928A1 (en) * 2002-04-09 2003-10-27 7Tm Pharma A/S Novel aminotetraline compounds for use in mch receptor related disorders
US7078430B2 (en) * 2002-07-08 2006-07-18 Ranbaxy Laboratories Limited HMG CoA-reductase inhibitors
FR2842524B1 (en) * 2002-07-16 2005-04-22 Aventis Pharma Sa PHARMACEUTICAL COMPOSITIONS CONTAINING 3-GUANIDINOCARBONYL-1-HETEROARYL-PYRROLE DERIVATIVE, PROCESS FOR PREPARING THE SAME AS MEDICAMENTS
US7091235B2 (en) * 2002-10-15 2006-08-15 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1654225A4 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504412B2 (en) 2003-08-15 2009-03-17 Banyu Pharmaceuticals, Co., Ltd. Imidazopyridine derivatives
JP2008536824A (en) * 2005-04-01 2008-09-11 イーライ リリー アンド カンパニー Histamine H3 receptor drug, formulation and therapeutic use
US7803816B2 (en) 2005-09-30 2010-09-28 Hoffmann-La Roche Inc. MCH receptor antagonists
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US10093624B2 (en) 2010-11-15 2018-10-09 Abbvie Inc. NAMPT and ROCK inhibitors
US9302989B2 (en) 2010-11-15 2016-04-05 Abbvie Inc. NAMPT and rock inhibitors
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2016166684A1 (en) 2015-04-15 2016-10-20 Richter Gedeon Nyrt. Indole derivatives
US10329296B2 (en) 2015-04-15 2019-06-25 Richter Gedeon Nyrt. Indole derivatives

Also Published As

Publication number Publication date
CA2534428A1 (en) 2005-03-03
JP2007502283A (en) 2007-02-08
MXPA06001638A (en) 2006-04-28
US20050256161A1 (en) 2005-11-17
EP1654225A4 (en) 2007-11-28
WO2005019240A3 (en) 2005-05-06
EP1654225A2 (en) 2006-05-10
AU2004266228A2 (en) 2005-03-03
AU2004266228A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
EP1654225A2 (en) Melanin concentrating hormone receptor antagonists
US7659276B2 (en) Melanin concentrating hormone receptor antagonist
US7998959B2 (en) Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
JP4592077B2 (en) 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1 (NK-1) antagonists for the treatment of vomiting, depression, anxiety and cough
EP1539747B1 (en) N-aroyl cyclic amines as orexin receptor antagonists
AU638096B2 (en) Novel benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists, their methods of preparation, synthesis intermediates and pharmaceutical compositions in which they are present
CA2806051C (en) Cyclic n,n&#39;-diarylthioureas and n,n&#39;-diarylureas - androgen receptor antagonists, anticancer agent, method for preparation and use thereof
HU222112B1 (en) N-containing cyclic compounds, pharmaceutical compositions containing them, and process for producing them
DE19952146A1 (en) Arylalkanes, arylalkenes and aryl-azaalkanes, medicaments containing these compounds and process for their preparation
TW201105667A (en) Dihydronaphthyridinyl and related compounds for use in treating ophthalmological disorders
JP2011502135A (en) 7-azaindole derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
KR20180016485A (en) Positive allosteric modulator of muscarinic M2 receptor
US6495542B1 (en) Benzamide derivatives as vasopressin antagonists
JP4851085B2 (en) Pyrrolidine derivatives as oxytocin antagonists
AU2013283488A1 (en) A phenyl triazole derivative and its use for modulating the GABAA receptor complex
AU2004292546A1 (en) Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain
JP2006516144A (en) Thiazole compounds as integrin receptor antagonist derivatives
EP1572691A1 (en) Pyrazole compounds as integrin receptor antagonists derivatives
NZ313726A (en) Imidazopyridine derivatives and medicaments thereof
NZ786241A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004266228

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004780754

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2534428

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2004266228

Country of ref document: AU

Date of ref document: 20040811

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004266228

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/001638

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006523322

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004780754

Country of ref document: EP